###begin article-title 0
###xml 91 92 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 92 94 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">S&#8414;</xref>
beta-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation*Sâƒž
###end article-title 0
###begin p 1
###xml 231 262 231 262 <email xmlns:xlink="http://www.w3.org/1999/xlink">lefko001@receptor-biol.duke.edu</email>
 Investigator with the Howard Hughes Medical Institute. Founder of Trevena Inc., all other authors declare no competing financial interest. To whom correspondence should be addressed. Tel.: 919-684-2974; Fax: 919-684-8875; E-mail: lefko001@receptor-biol.duke.edu.
###end p 1
###begin p 2
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 2
###begin p 3
 applies to Author Choice Articles
###end p 3
###begin p 4
###xml 469 472 <span type="species:ncbi:10116">rat</span>
beta-Arrestins, originally discovered as terminators of G protein-coupled receptor signaling, have more recently been appreciated to also function as signal transducers in their own right, although the consequences for cellular physiology have not been well understood. Here we demonstrate that beta-arrestin-2 mediates anti-apoptotic cytoprotective signaling stimulated by a typical 7-transmembrane receptor the angiotensin ATII 1A receptor, expressed endogenously in rat vascular smooth muscle cells or by transfection in HEK-293 cells. Receptor stimulation leads to concerted activation of two pathways, ERK/p90RSK and PI3K/AKT, which converge to phosphorylate and inactivate the pro-apoptotic protein BAD. Anti-apoptotic effects as well as pathway activities can be stimulated by an angiotensin analog (SII), which has been previously shown to activate beta-arrestin but not G protein-dependent signaling, and are abrogated by beta-arrestin-2 small interfering RNA. These findings establish a key role for beta-arrestin-2 in mediating cellular cytoprotective functions by a 7-transmembrane receptor and define the biochemical pathways involved.
###end p 4
###begin p 5
###xml 49 78 49 78 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 86 93 86 93 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">HL16037</grant-num>
###xml 98 105 98 105 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">HL70631</grant-num>
###xml 248 261 248 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported, in whole or in part, by National Institutes of Health Grants HL16037 and HL70631. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 5
###begin p 6
The on-line version of this article (available at ) contains supplemental Figs. S1 and S2.
###end p 6
###begin p 7
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 7
###begin p 8
###xml 127 128 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn4">2</xref>
###xml 303 304 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 471 472 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 790 791 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 792 794 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 880 881 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1083 1084 1065 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 1346 1347 1318 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 962 967 <span type="species:ncbi:10090">mouse</span>
beta-Arrestins 1 and 2 were originally identified as signal terminators for G protein-dependent 7-transmembrane receptor (7TMR)2 signaling. Their binding to the receptor sterically inhibits receptor coupling to G protein leading to inactivation of effectors such as second messenger generating enzymes (1). Besides this classical function, recently accumulating evidence has revealed novel functions of beta-arrestins as signal transducers in various signaling pathways (2). Among other processes, beta-arrestins have been suggested to play a role in regulation of cell death, but this area has been controversial and largely devoid of mechanistic insight. There have been reports implicating beta-arrestins in both pro- and anti-apoptotic responses as well as in non-apoptotic cell death (3-10). For example, it has been shown that stimulation of a number of 7TMRs including the N-formyl peptide receptor induces apoptosis in beta-arrestin 1/2 double knock-out mouse embryonic fibroblasts, and that reintroduction of either beta-arrestin-1 or -2 completely prevents this apoptosis (5). Conversely, beta-arrestins also have been reported to mediate cell death. beta-Arrestin-2, particularly a dephosphorylated form, has been shown to facilitate inhibition of NF-kappaB activation in response to UV, leading to promotion of UV-induced cell death (8).
###end p 8
###begin p 9
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 1039 1040 1039 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
Bcl-2 family proteins are known to determine the outcome of an intrinsic apoptotic process initiated by release of cytochrome c and apoptotic factors from the mitochondria (11). BAD, a BH3-only protein is one of the "death-promoting" members of the Bcl-2 family and its pro-apoptotic activity is regulated primarily by phosphorylation at several sites (12, 13). Survival factors induce BAD phosphorylation via several protein kinase signaling pathways (13) including activation of mitogen-activated protein kinase (MAPK)-ribosomal S6 kinase (RSK) (14-16) and phosphatidylinositol 3-kinase (PI3K)-AKT (17, 18). Phosphorylated BAD associates with 14-3-3 proteins in the cytoplasm, preventing translocation of BAD to the mitochondria (19) and its interaction with the anti-apoptotic proteins Bcl-xL and Bcl-2 (13, 20). These proteins, freed from BAD, in turn associate with two other pro-apoptotic proteins, BAX and BAK. Such association prevents aggregation of these pro-apoptotic proteins on the mitochondrial membrane, stopping cytochrome c release and consequently inhibiting apoptosis (11, 20).
###end p 9
###begin p 10
###xml 171 172 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 287 289 281 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 292 294 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 296 298 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 314 315 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 317 319 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 343 345 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 356 357 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 380 382 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 526 528 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 529 531 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 546 548 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 550 552 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 636 638 624 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1037 1039 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1208 1214 1190 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 1410 1412 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 1436 1437 1415 1416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1553 1555 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 1557 1559 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 688 693 <span type="species:ncbi:9606">human</span>
Recently several 7TMRs have been shown to activate the extracellular signal-regulated kinase (ERK) MAPK cascade and PI3K-AKT pathways in a beta-arrestin-dependent manner (2). In particular, it has been demonstrated that beta-arrestin-mediated ERK activation by angiotensin II type 1A (AT1A) (21, 22), vasopressin V2 (23), parathyroid hormone (24), and beta2-adrenergic receptors (25) is G protein-independent. Furthermore, we have previously found that beta-arrestin-mediated ERK activation is quite distinct in its temporal (22-25) and spatial (22, 26) patterns from ERK-activated via G protein-dependent stimulation. In the case of AT1AR-mediated ERK activation in receptor-transfected human embryonic kidney (HEK)-293 cells, for example, the G protein-dependent activation is rapid, quite transient (peak at 2-5 min), and leads to nuclear translocation of the activated ERK. In contrast, beta-arrestin-2-dependent ERK activation is slower, quite persistent, and entirely confined to the cytoplasm, particularly to endosomal vesicles (22). Such differences in ERK activation strongly imply that there must be subsets of ERK targets and physiological outcomes differentially regulated through beta-arrestin versus G protein-dependent mechanisms. In the case of AKT activation, stimulation of 7TM protease-activated receptors with thrombin has been shown to activate AKT in a beta-arrestin-1-dependent manner (27). Stimulation of the AT1 receptor also has been shown to activate AKT in several cell types including vascular smooth muscle cells (VSMCs) (28, 29) although it has not been determined whether beta-arrestins are involved in this signaling.
###end p 10
###begin p 11
###xml 292 293 289 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 306 309 <span type="species:ncbi:10116">rat</span>
Accordingly, the studies reported here were undertaken to examine the role of beta-arrestin in 7TMR-regulated apoptosis and to determine the downstream pathways mediating this regulation in a physiologically relevant non-transfected cellular receptor system. For this purpose, we chose the AT1 receptor in rat VSMCs.
###end p 11
###begin title 12
EXPERIMENTAL PROCEDURES
###end title 12
###begin p 13
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Materials</italic>
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
Materials-[Sar1,Ile4,Ile8]AngII (Sar-Arg-Val-Ile-Ile-His-Pro-Ile) (SII) was synthesized as described (21, 30). GF109203X (GFX), Ro-31-8425, U0126, and Z-VAD-fmk were purchased from Calbiochem. SL0101 was from Toronto Research Chemicals (North York, Ontario, Canada). All other reagents were purchased from Sigma, unless otherwise described. Plasmids expressing hemagglutinin-tagged wild-type, S112A and S136A mutant BAD were a generous gift from Dr. Michael E. Greenberg (Harvard Medical School).
###end p 13
###begin p 14
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Antibodies</italic>
###xml 45 48 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 131 134 131 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">112</sup>
###xml 241 244 241 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">175</sup>
###xml 276 279 276 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">202</sup>
###xml 283 286 283 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">204</sup>
###xml 322 325 322 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">359</sup>
###xml 329 332 329 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">363</sup>
###xml 850 852 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 11 17 <span type="species:ncbi:9986">Rabbit</span>
###xml 168 173 <span type="species:ncbi:9606">human</span>
###xml 477 482 <span type="species:ncbi:10090">mouse</span>
###xml 517 522 <span type="species:ncbi:9606">human</span>
###xml 606 609 <span type="species:ncbi:10116">rat</span>
###xml 764 769 <span type="species:ncbi:9606">Human</span>
###xml 774 777 <span type="species:ncbi:10116">rat</span>
Antibodies-Rabbit polyclonal phospho-AKT (Ser473) (used in an 1:1,000 dilution for immunoblotting), AKT (1:2,000), phospho-BAD (Ser112) (1:500-1,000), BAD (1:1,000 for human BAD), Bcl-xL (1:1,000), caspase-3 (1:1,000), cleaved caspase-3 (Asp175) (1:1,000), phospho-ERK1/2 (Thr202/Tyr204) (1:2,000), and phospho-p90RSK (Thr359/Ser363) (1:500-1,000) antibodies were purchased from Cell Signaling (Danvers, MA). Polyclonal 14-3-3beta (C-20) (1:1,000), RSK-1 (C-21) (1:1,000), and mouse monoclonal BAD (C-7) (1:1,000 for human BAD) antibodies were from Santa Cruz (Santa Cruz, CA). Monoclonal BAD (1:2,000 for rat BAD) and polyclonal ERK1/2 (1:10,000) antibodies were from BD Transduction Laboratories (Franklin Lakes, NJ) and Millipore (Billerica, MA), respectively. Human and rat beta-arrestins were detected by A1CT and A2CT antibodies, respectively (31).
###end p 14
###begin p 15
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Synthesis of Small Interfering RNAs (siRNAs)</italic>
###xml 484 486 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 283 288 <span type="species:ncbi:9606">human</span>
###xml 290 293 <span type="species:ncbi:10116">rat</span>
Synthesis of Small Interfering RNAs (siRNAs)-Chemically synthesized, double-stranded siRNAs, with 19-nucleotide duplex RNA and 2-nucleotide 3'-dTdT overhangs were purchased from Dharmacon (Lafayette, CO) in deprotected and desalted forms. The two different siRNA sequences targeting human (rat) beta-arrestin-2 were 5'-GGACCGC(G)AAAGUGUUUGUG-3' and 5'-CCAACCUCAUUGAAUUU(C)GA-3', corresponding to positions 150-168 and 1112(1115)-1131(1133), relative to the start codon, respectively (32). A non-silencing RNA duplex (5'-UUCUCCGAACGUGUCACGU-3'), as the manufacturer (Xeragon, Germantown, MD) indicated, was used as a control.
###end p 15
###begin p 16
###xml 0 29 0 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cell Culture and Transfection</italic>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 1334 1336 1324 1326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1449 1451 1427 1429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1740 1742 1717 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 69 88 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 841 847 <span type="species:ncbi:9913">bovine</span>
Cell Culture and Transfection-VSMCs were isolated from aorta of male Sprague-Dawley rats and maintained as described (32). Eight to 90% confluent early passage (<5) VSMCs were transfected with siRNA using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the modified manufacturer's instructions. Briefly, 60 mul of the Lipofectamine 2000 transfection reagent was added to 300 mul of the medium-199 and 20 mug of siRNA was added to 400 mul of the medium. Both solutions were allowed to stand 5-10 min at room temperature and mixed by inversion. Following a 15-20-min incubation at room temperature, the entire transfection mixture was added to VSMCs in a 100-mm dish containing 5 ml of the fresh, serum-free medium. After cells were incubated for overnight at 37 degreesC, an additional 5 ml of the medium with 20% fetal bovine serum and 2% penicillin/streptomycin were added to the dish. Following an additional incubation for 24 h, cells were divided into 6-well plates or 35-mm glass bottom dishes (MatTek, Ashland, MA) for further procedures. For DNA transfection into VSMCs in either 35-mm glass bottom dishes or 6-well plates, the Lipofectamine LTX transfection reagent (Invitrogen) was used with the PLUS reagent (Invitrogen) according to the manufacturer's instructions. HEK-293 cells, stably expressing AT1A receptors (approximately600 fmol/mg of proteins), were established after transfection with a zeocin-resistant AT1A receptor expression plasmid using FuGENE 6 (Roche) according to the manufacturer's instructions. Stable clones were selected in the presence of zeocin (300 mug/ml) (Invitrogen). Cells were maintained and transfected with siRNAs using GeneSilencer (Genlantis, San Diego, CA) as described (22).
###end p 16
###begin p 17
###xml 0 46 0 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cleaved Caspase-3 and DNA Fragmentation Assays</italic>
###xml 124 125 112 113 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 140 141 127 128 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 207 208 187 188 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 210 211 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 212 213 192 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 222 223 201 202 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 568 572 547 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">PLUS</sup>
Cleaved Caspase-3 and DNA Fragmentation Assays-VSMCs were serum-starved for approximately24 h and then stimulated with 100 nm AngII or 10 mum SII at 37 degreesC for 5 min prior to treatment with either 80 mum H2O2 or 50 mum etoposide. After a further incubation overnight, cell lysates were prepared. Pro- and cleaved caspase-3 were visualized, and the amounts of cleaved caspase-3 were quantified as described for immunoblotting in this section. The amounts of fragmented DNA were measured by the enzyme-linked immunosorbent assay using the Cell Death Detection ELISAPLUS kit (Roche) according to the manufacturer's instructions.
###end p 17
###begin p 18
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunostaining</italic>
###xml 336 337 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 236 242 <span type="species:ncbi:9913">bovine</span>
###xml 303 308 <span type="species:ncbi:10090">mouse</span>
Immunostaining-VSMCs on 35-mm glass bottom dishes were fixed with 5% formaldehyde diluted in phosphate-buffered saline (PBS). Fixed cells were permeabilized by incubation with 0.2% Triton X-100 in PBS for 20 min. After blocking with 2% bovine serum albumin in PBS for 1 h, cells were incubated with the mouse monoclonal anti-cytochrome c (BD Pharmingen, 1:100) antibody at room temperature for 2 h, and repeatedly washed with PBS. Next, incubation of the Bodipy fluorescein-conjugated secondary antibody (Molecular Probes, 1:100) was done for 1 h at room temperature followed by repeated washes with PBS. For subsequent staining of the hemaglutinin epitope-tagged BAD, cells were incubated with a polyclonal hemaglutinin probe (Y11) antibody (Santa Cruz, 1:200) at room temperature overnight. The Texas Red-conjugated secondary antibody (Molecular Probes, 1:250) was then added for 1 h. Confocal images were obtained on a Zeiss LSM510 laser scanning microscope using single line (488 nm) or multitrack sequential excitation (488 and 568 nm) and emission (515-540 nm, Bodipy fluorescein; 585-615 nm, Texas Red) filter sets.
###end p 18
###begin p 19
###xml 0 38 0 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunoblotting and Immunoprecipitation</italic>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 376 378 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 510 512 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 636 642 <span type="species:ncbi:9986">rabbit</span>
###xml 676 681 <span type="species:ncbi:10090">mouse</span>
Immunoblotting and Immunoprecipitation-In most cases, cellular extracts from VSMCs or HEK-293 cells on 6-well plates were prepared as described previously (22). For caspase-3 immunoblotting, VSMC lysates were prepared using the RIPA lysis buffer. Equal amounts (approximately10 mug) of cellular extracts/lysates were used for immunoblotting performed as described previously (22). For immunoprecipitation, lysates form HEK-293 cells in 100-mm dishes were prepared using the glycerol/Nonidet P-40 lysis buffer (33). Equal amounts of cell lysates (300-500 mug of total protein in 1 ml of the buffer) were incubated with 1-2 mug of either rabbit polyclonal 14-3-3 beta (C-20) or mouse monoclonal BAD (C-7) antibody and protein A- or G-agarose beads, respectively, overnight at 4 degreesC. Co-immunoprecipitated proteins were detected by immunoblotting. Each band in immunoblots was quantified by densitometry using the GeneTools program (SynGene).
###end p 19
###begin p 20
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Statistical Analysis</italic>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 273 279 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 565 566 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 574 575 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 577 578 574 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 587 589 584 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">**</sup>
###xml 591 592 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 601 604 598 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 606 607 603 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Statistical Analysis-Statistical significance in bar graphs was determined by using a one-way analysis of variance (PRISM software) to correct for multiple comparisons (Bonferroni's multiple comparison test) or t test for single comparisons between AngII or SII-stimulated versus non-stimulated in a certain condition, unless otherwise indicated in each figure. Statistical significance in each time point of kinetic graphs was determined by using a two-way analysis of variance (Bonferroni's post-test) between beta-arrestin-2 siRNA-transfected and control cells. p value (*, p < 0.05; **, p < 0.01; ***, p < 0.001) of <0.05 was considered statistically significant.
###end p 20
###begin title 21
RESULTS
###end title 21
###begin p 22
###xml 4 117 1 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-2 Is Essential for the Anti-apoptotic Effects of AngII on Primary Cultured Vascular Smooth Muscle Cells</italic>
###xml 277 278 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 283 285 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 287 289 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 380 382 374 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 409 411 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 413 415 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 543 545 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 863 864 848 849 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1072 1074 1057 1059 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1077 1079 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 1134 1135 1119 1120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1136 1137 1121 1122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1146 1147 1131 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1140 1147 1125 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 1169 1170 1154 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1163 1170 1148 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 1374 1375 1347 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1380 1381 1353 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1366 1381 1339 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>C</italic> and <italic>D</italic></xref>
###xml 1761 1762 1716 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1767 1768 1722 1723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1753 1768 1708 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>C</italic> and <italic>D</italic></xref>
beta-Arrestin-2 Is Essential for the Anti-apoptotic Effects of AngII on Primary Cultured Vascular Smooth Muscle Cells-It has been previously reported that the octapeptide hormone angiotensin II (AngII) promotes anti-apoptotic effects in VSMCs through AngII type 1 receptors (AT1Rs) (34, 35). We and others have previously found that beta-arrestin-2 is the isoform that mediates AT1AR-activated ERK signaling (33, 36), which is potentially an anti-apoptotic pathway. We have also found that beta-arrestin-1 functionally opposes this signaling (33). Consequently, we used VSMCs to explore the role of beta-arrestin-2 in regulating apoptosis. We first monitored the effects of AngII stimulation on the activation of caspase-3 (cleavage of procaspase-3) induced by apoptotic challenges in VSMCs transfected with either control or beta-arrestin-2 siRNAs. We used 100 nm AngII to obtain maximal responses in this assay. It has been previously reported that AngII-stimulated ERK activation reaches maximal levels with this concentration in HEK-293 cells transiently expressing AT1AR (33). Apoptotic stimulation by either hydrogen peroxide (H2O2) (Fig. 1A) or etoposide (Fig. 1B) dramatically increases the level of cleaved caspase-3 in control VSMCs. The levels of cleaved caspase-3 induced by such apoptotic stimuli were reduced to approximately50% by AngII pretreatment (Fig. 1, C and D). Next, we examined the effects of siRNA-mediated beta-arrestin-2 knock-down on AngII-promoted protection from caspase-3 cleavage. Depletion of beta-arrestin-2 not only leads to increases (up to approximately150%) in the induction of cleaved caspase-3 levels by treatment with hydrogen peroxide or etoposide, but also eliminates AngII-mediated decreases in these levels (Fig. 1, C and D). On the other hand, knocking-down beta-arrestin-1 leads to decreases in apoptotic reagent-induced caspase-3 cleavage even in the absence of stimulation with AngII, which is similar in extent to the protection observed in AngII-treated control cells. Stimulation with AngII results in no significant further protection in cells knocked down for beta-arrestin-1 (data not shown). These results suggest an essential role of beta-arrestin-2 in AngII-stimulated protection from caspase-dependent apoptotic processes.
###end p 22
###begin p 23
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 359 360 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 448 449 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 442 449 439 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 451 467 448 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper left panel</italic>
###xml 544 545 541 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 596 597 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 590 597 587 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 599 617 596 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper middle panel</italic>
###xml 675 676 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 736 737 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 730 737 727 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 739 756 736 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper right panel</italic>
###xml 797 798 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 976 977 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 993 994 990 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 987 994 984 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 1224 1226 1221 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 1228 1230 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
###xml 1321 1322 1315 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1315 1322 1309 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 1324 1340 1318 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower left panel</italic>
###xml 1441 1442 1435 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1435 1442 1429 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 1444 1462 1438 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower middle panel</italic>
###xml 1666 1667 1657 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1660 1667 1651 1658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 1669 1686 1660 1677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower right panel</italic>
###xml 848 852 <span type="species:ncbi:262676">Mito</span>
Because the release of cytochrome c from mitochondria is one of the key upstream events for the coordinated activation of caspases (34, 37), we next examined effects of AngII stimulation on the hydrogen peroxide-induced redistribution of cytochrome c in control or beta-arrestin-2 siRNA-transfected VSMCs. In the absence of an apoptotic challenge, cytochrome c is well distributed within cytoplasmic, mitochondrial networks in control cells (Fig. 1E, upper left panel). Treatment with hydrogen peroxide leads to the rearrangement of cytochrome c into a cytoplasmic dotted pattern in cells (Fig. 1E, upper middle panel). Hydrogen peroxide-induced redistribution of cytochrome c is largely reversed by prior stimulation with AngII (Fig. 1E, upper right panel). These staining patterns of cytochrome c are, in all cases, superimposed with that of the Mito-Tracker, a mitochondrial marker (supplemental Fig. S1), confirming that the changes in the staining patterns of cytochrome c shown in Fig. 1E indeed represent mitochondrial remodeling. Mitochondrial rearrangement and fragmentation have been observed in apoptotic cells, especially when apoptosis has been induced by pro-apoptotic members of the Bcl-2 family of proteins (38, 39). Depletion of beta-arrestin-2 has no effect on mitochondrial network organization (Fig. 1E, lower left panel), and does not alter the pattern of fragmentation observed after hydrogen peroxide treatment (Fig. 1E, lower middle panel). However, unlike control siRNA-transfected cells, pre-stimulation with AngII fails to reverse the hydrogen peroxide-induced mitochondrial fragmentation in beta-arrestin-2 siRNA-transfected cells (Fig. 1E, lower right panel). These results further support an important role for beta-arrestin-2 in mediating AngII-stimulated anti-apoptotic activity.
###end p 23
###begin p 24
###xml 201 202 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 195 202 192 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>F</italic></xref>
###xml 224 225 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 218 225 215 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>G</italic></xref>
###xml 435 436 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 441 442 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 427 442 412 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>F</italic> and <italic>G</italic></xref>
###xml 596 597 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 602 603 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 588 603 570 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>F</italic> and <italic>G</italic></xref>
To further validate these findings, we measured DNA fragmentation, a hallmark of cell death, in VSMCs transfected with either control or beta-arrestin-2 siRNAs. Treatment with hydrogen peroxide (Fig. 1F) or etoposide (Fig. 1G) causes a 4-6-fold increase in DNA fragmentation. In control siRNA-transfected cells, pre-stimulation with AngII reduces (by approximately40%) the extent of DNA fragmentation induced by both reagents (Fig. 1, F and G). On the contrary, we did not observe decreases in DNA fragmentation after prestimulation with AngII in beta-arrestin-2 siRNA-transfected cells (Fig. 1, F and G), mirroring the situation observed with caspase-3 activation. In the case of beta-arrestin-1 knock-down, effects on DNA fragmentation also mirror the effects observed with caspase-3 cleavage (data not shown). Taken together, these results demonstrate that beta-arrestin-2 is crucial for AngII-stimulated protection of VSMCs from apoptotic cell death.
###end p 24
###begin p 25
###xml 53 54 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 205 206 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 210 211 207 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 215 216 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 305 307 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 309 311 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 334 335 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 340 341 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 326 341 323 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>H</italic> and <italic>I</italic></xref>
###xml 629 630 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 623 630 620 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>J</italic></xref>
###xml 804 805 801 802 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
To establish whether the beta-arrestin-2-dependent AT1R-mediated inhibition of apoptotic processes can be accomplished in the absence of G protein activation, we stimulated VSMCs with an AngII analog, [Sar1,Ile4,Ile8]AngII (SII). This mutant form of AngII was previously shown not to activate G proteins (21, 30). As shown in Fig. 1, H and I, stimulation of the cells with SII leads to significant decreases (35-45%) in the levels of cleaved caspase-3 upon hydrogen peroxide or etoposide treatment. The extent of DNA fragmentation induced by these reagents is also reduced to a similar extent upon prestimulation with SII (Fig. 1J). The extent of SII-stimulated decreases (30-45%) in both assays is similar to those evoked by AngII stimulation (40-50%). This result demonstrates that activation of the AT1 receptor elicits cytoprotective effects mainly through G protein-independent signaling.
###end p 25
###begin p 26
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 13 149 10 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-2, but not activation of G proteins, is essential for AngII-promoted cytoprotection against apoptotic challenges in rat VSMCs.</bold>
###xml 149 152 146 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-G</italic>
###xml 215 218 212 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTL</italic>
###xml 273 277 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arr2</italic>
###xml 287 288 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 293 294 284 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 344 345 335 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 346 347 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 349 350 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 366 367 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 487 489 478 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 492 493 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 498 499 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 617 618 608 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 619 620 610 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 622 623 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 640 641 631 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 776 777 765 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 784 785 772 773 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 904 905 880 881 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 906 907 882 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 955 956 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1075 1076 1051 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1081 1082 1057 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1100 1101 1076 1077 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1102 1103 1078 1079 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1105 1106 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1123 1124 1099 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1339 1341 1315 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NT</italic>
###xml 1447 1450 1421 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-J</italic>
###xml 1515 1516 1489 1490 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1517 1518 1491 1492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1580 1581 1554 1555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1586 1587 1560 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1609 1610 1583 1584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 1712 1713 1684 1685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1721 1722 1693 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 9 1834 9 1806 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">&#946;<bold>-Arrestin-2, but not activation of G proteins, is essential for AngII-promoted cytoprotection against apoptotic challenges in rat VSMCs.</bold><italic>A-G</italic>, primary cultured VSMCs were transfected with either control (<italic>CTL</italic>) or simultaneously two different &#946;-arrestin-2 (&#946;<italic>arr2</italic>) siRNAs. <italic>A</italic> and <italic>B</italic>, cells were stimulated with AngII before either H<sub>2</sub>O<sub>2</sub> (<italic>A</italic>) or etoposide (<italic>B</italic>) treatment as described under &#8220;Experimental Procedures.&#8221; Pro- and cleaved caspase-3 were visualized by immunoblotting (<italic>IB</italic>). <italic>C</italic> and <italic>D</italic>, contents of cleaved caspase-3 in the immunoblots were quantified and expressed as percent of the level obtained in H<sub>2</sub>O<sub>2</sub>-(<italic>C</italic>) or etoposide- (<italic>D</italic>) treated cells in the absence of stimulation with AngII. Data represent the mean &#177; S.E. from at least five independent experiments. <italic>E</italic>, 50 &#956;<sc>m</sc> Z-VAD-fmk was treated to block caspase-dependent cell death before stimulation with AngII. At &#8764;6 h after H<sub>2</sub>O<sub>2</sub> treatment, cellular distribution of cytochrome <italic>c</italic> was visualized by immunostaining. Images shown represent similar results obtained from three independent experiments. <italic>F</italic> and <italic>G</italic>, the amounts of H<sub>2</sub>O<sub>2</sub>-(<italic>F</italic>) or etoposide- (<italic>G</italic>) induced DNA fragmentation in the absence or presence of stimulation with AngII were measured as described under &#8220;Experimental Procedures.&#8221; Values were expressed as folds over basal in non-stimulated, non-treated (<italic>NT</italic>), CTL-siRNA-transfected cells and represent the mean &#177; S.E. from at least six independent experiments. <italic>H-J</italic>, VSMCs were stimulated with SII prior to treatment with either H<sub>2</sub>O<sub>2</sub> or etoposide as indicated. The amounts of cleaved caspase-3 (<italic>H</italic> and <italic>I</italic>) and fragmented DNA (<italic>J</italic>) were determined and expressed as described above. Data represent the mean &#177; S.E. from at least 5 (<italic>I</italic>) or 6 (<italic>J</italic>) independent experiments. All statistical analyses were performed as described under &#8220;Experimental Procedures.&#8221;</p>
###xml 9 1834 9 1806 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">&#946;<bold>-Arrestin-2, but not activation of G proteins, is essential for AngII-promoted cytoprotection against apoptotic challenges in rat VSMCs.</bold><italic>A-G</italic>, primary cultured VSMCs were transfected with either control (<italic>CTL</italic>) or simultaneously two different &#946;-arrestin-2 (&#946;<italic>arr2</italic>) siRNAs. <italic>A</italic> and <italic>B</italic>, cells were stimulated with AngII before either H<sub>2</sub>O<sub>2</sub> (<italic>A</italic>) or etoposide (<italic>B</italic>) treatment as described under &#8220;Experimental Procedures.&#8221; Pro- and cleaved caspase-3 were visualized by immunoblotting (<italic>IB</italic>). <italic>C</italic> and <italic>D</italic>, contents of cleaved caspase-3 in the immunoblots were quantified and expressed as percent of the level obtained in H<sub>2</sub>O<sub>2</sub>-(<italic>C</italic>) or etoposide- (<italic>D</italic>) treated cells in the absence of stimulation with AngII. Data represent the mean &#177; S.E. from at least five independent experiments. <italic>E</italic>, 50 &#956;<sc>m</sc> Z-VAD-fmk was treated to block caspase-dependent cell death before stimulation with AngII. At &#8764;6 h after H<sub>2</sub>O<sub>2</sub> treatment, cellular distribution of cytochrome <italic>c</italic> was visualized by immunostaining. Images shown represent similar results obtained from three independent experiments. <italic>F</italic> and <italic>G</italic>, the amounts of H<sub>2</sub>O<sub>2</sub>-(<italic>F</italic>) or etoposide- (<italic>G</italic>) induced DNA fragmentation in the absence or presence of stimulation with AngII were measured as described under &#8220;Experimental Procedures.&#8221; Values were expressed as folds over basal in non-stimulated, non-treated (<italic>NT</italic>), CTL-siRNA-transfected cells and represent the mean &#177; S.E. from at least six independent experiments. <italic>H-J</italic>, VSMCs were stimulated with SII prior to treatment with either H<sub>2</sub>O<sub>2</sub> or etoposide as indicated. The amounts of cleaved caspase-3 (<italic>H</italic> and <italic>I</italic>) and fragmented DNA (<italic>J</italic>) were determined and expressed as described above. Data represent the mean &#177; S.E. from at least 5 (<italic>I</italic>) or 6 (<italic>J</italic>) independent experiments. All statistical analyses were performed as described under &#8220;Experimental Procedures.&#8221;</p></caption>
###xml 1834 1834 1806 1806 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0170971160001"/>
###xml 0 1834 0 1806 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="27">&#946;<bold>-Arrestin-2, but not activation of G proteins, is essential for AngII-promoted cytoprotection against apoptotic challenges in rat VSMCs.</bold><italic>A-G</italic>, primary cultured VSMCs were transfected with either control (<italic>CTL</italic>) or simultaneously two different &#946;-arrestin-2 (&#946;<italic>arr2</italic>) siRNAs. <italic>A</italic> and <italic>B</italic>, cells were stimulated with AngII before either H<sub>2</sub>O<sub>2</sub> (<italic>A</italic>) or etoposide (<italic>B</italic>) treatment as described under &#8220;Experimental Procedures.&#8221; Pro- and cleaved caspase-3 were visualized by immunoblotting (<italic>IB</italic>). <italic>C</italic> and <italic>D</italic>, contents of cleaved caspase-3 in the immunoblots were quantified and expressed as percent of the level obtained in H<sub>2</sub>O<sub>2</sub>-(<italic>C</italic>) or etoposide- (<italic>D</italic>) treated cells in the absence of stimulation with AngII. Data represent the mean &#177; S.E. from at least five independent experiments. <italic>E</italic>, 50 &#956;<sc>m</sc> Z-VAD-fmk was treated to block caspase-dependent cell death before stimulation with AngII. At &#8764;6 h after H<sub>2</sub>O<sub>2</sub> treatment, cellular distribution of cytochrome <italic>c</italic> was visualized by immunostaining. Images shown represent similar results obtained from three independent experiments. <italic>F</italic> and <italic>G</italic>, the amounts of H<sub>2</sub>O<sub>2</sub>-(<italic>F</italic>) or etoposide- (<italic>G</italic>) induced DNA fragmentation in the absence or presence of stimulation with AngII were measured as described under &#8220;Experimental Procedures.&#8221; Values were expressed as folds over basal in non-stimulated, non-treated (<italic>NT</italic>), CTL-siRNA-transfected cells and represent the mean &#177; S.E. from at least six independent experiments. <italic>H-J</italic>, VSMCs were stimulated with SII prior to treatment with either H<sub>2</sub>O<sub>2</sub> or etoposide as indicated. The amounts of cleaved caspase-3 (<italic>H</italic> and <italic>I</italic>) and fragmented DNA (<italic>J</italic>) were determined and expressed as described above. Data represent the mean &#177; S.E. from at least 5 (<italic>I</italic>) or 6 (<italic>J</italic>) independent experiments. All statistical analyses were performed as described under &#8220;Experimental Procedures.&#8221;</p></caption><graphic xlink:href="zbc0170971160001"/></fig>
###xml 139 142 <span type="species:ncbi:10116">rat</span>
FIGURE 1.beta-Arrestin-2, but not activation of G proteins, is essential for AngII-promoted cytoprotection against apoptotic challenges in rat VSMCs.A-G, primary cultured VSMCs were transfected with either control (CTL) or simultaneously two different beta-arrestin-2 (betaarr2) siRNAs. A and B, cells were stimulated with AngII before either H2O2 (A) or etoposide (B) treatment as described under "Experimental Procedures." Pro- and cleaved caspase-3 were visualized by immunoblotting (IB). C and D, contents of cleaved caspase-3 in the immunoblots were quantified and expressed as percent of the level obtained in H2O2-(C) or etoposide- (D) treated cells in the absence of stimulation with AngII. Data represent the mean +/- S.E. from at least five independent experiments. E, 50 mum Z-VAD-fmk was treated to block caspase-dependent cell death before stimulation with AngII. At approximately6 h after H2O2 treatment, cellular distribution of cytochrome c was visualized by immunostaining. Images shown represent similar results obtained from three independent experiments. F and G, the amounts of H2O2-(F) or etoposide- (G) induced DNA fragmentation in the absence or presence of stimulation with AngII were measured as described under "Experimental Procedures." Values were expressed as folds over basal in non-stimulated, non-treated (NT), CTL-siRNA-transfected cells and represent the mean +/- S.E. from at least six independent experiments. H-J, VSMCs were stimulated with SII prior to treatment with either H2O2 or etoposide as indicated. The amounts of cleaved caspase-3 (H and I) and fragmented DNA (J) were determined and expressed as described above. Data represent the mean +/- S.E. from at least 5 (I) or 6 (J) independent experiments. All statistical analyses were performed as described under "Experimental Procedures."
###end p 26
###begin p 27
###xml 4 140 1 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-2, but not activation of G proteins, is essential for AngII-promoted cytoprotection against apoptotic challenges in rat VSMCs.</bold>
###xml 140 143 137 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-G</italic>
###xml 206 209 203 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTL</italic>
###xml 264 268 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arr2</italic>
###xml 278 279 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 284 285 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 335 336 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 337 338 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 340 341 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 357 358 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 478 480 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 483 484 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 489 490 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 608 609 599 600 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 610 611 601 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 613 614 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 631 632 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 767 768 756 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 775 776 763 764 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 895 896 871 872 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 897 898 873 874 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 946 947 922 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1066 1067 1042 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1072 1073 1048 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1091 1092 1067 1068 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1093 1094 1069 1070 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1096 1097 1072 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1114 1115 1090 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1330 1332 1306 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NT</italic>
###xml 1438 1441 1412 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-J</italic>
###xml 1506 1507 1480 1481 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1508 1509 1482 1483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1571 1572 1545 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1577 1578 1551 1552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1600 1601 1574 1575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 1703 1704 1675 1676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1712 1713 1684 1685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 130 133 <span type="species:ncbi:10116">rat</span>
beta-Arrestin-2, but not activation of G proteins, is essential for AngII-promoted cytoprotection against apoptotic challenges in rat VSMCs.A-G, primary cultured VSMCs were transfected with either control (CTL) or simultaneously two different beta-arrestin-2 (betaarr2) siRNAs. A and B, cells were stimulated with AngII before either H2O2 (A) or etoposide (B) treatment as described under "Experimental Procedures." Pro- and cleaved caspase-3 were visualized by immunoblotting (IB). C and D, contents of cleaved caspase-3 in the immunoblots were quantified and expressed as percent of the level obtained in H2O2-(C) or etoposide- (D) treated cells in the absence of stimulation with AngII. Data represent the mean +/- S.E. from at least five independent experiments. E, 50 mum Z-VAD-fmk was treated to block caspase-dependent cell death before stimulation with AngII. At approximately6 h after H2O2 treatment, cellular distribution of cytochrome c was visualized by immunostaining. Images shown represent similar results obtained from three independent experiments. F and G, the amounts of H2O2-(F) or etoposide- (G) induced DNA fragmentation in the absence or presence of stimulation with AngII were measured as described under "Experimental Procedures." Values were expressed as folds over basal in non-stimulated, non-treated (NT), CTL-siRNA-transfected cells and represent the mean +/- S.E. from at least six independent experiments. H-J, VSMCs were stimulated with SII prior to treatment with either H2O2 or etoposide as indicated. The amounts of cleaved caspase-3 (H and I) and fragmented DNA (J) were determined and expressed as described above. Data represent the mean +/- S.E. from at least 5 (I) or 6 (J) independent experiments. All statistical analyses were performed as described under "Experimental Procedures."
###end p 27
###begin p 28
###xml 4 134 1 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-2 Mediates Activation of ERK-RSK and AKT Signaling Pathways, Leading to Phosphorylation of BAD in AngII-stimulated VSMCs</italic>
###xml 269 270 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 305 307 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 308 310 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 321 323 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 665 666 656 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 667 668 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 657 668 648 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>A</italic>-<italic>C</italic></xref>
###xml 784 786 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1037 1039 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 1041 1043 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 1113 1115 1104 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 1117 1119 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 1192 1194 1180 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1196 1198 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 1448 1450 1436 1438 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1460 1461 1448 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn5">3</xref>
###xml 1628 1629 1613 1614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1634 1635 1619 1620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1620 1635 1605 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>D</italic> and <italic>E</italic></xref>
###xml 1730 1733 1715 1718 <sup xmlns:xlink="http://www.w3.org/1999/xlink">359</sup>
###xml 1737 1740 1722 1725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">363</sup>
###xml 1742 1744 1727 1729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 1746 1748 1731 1733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 1978 1984 1963 1969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1986 1996 1971 1981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C versus E</italic>
beta-Arrestin-2 Mediates Activation of ERK-RSK and AKT Signaling Pathways, Leading to Phosphorylation of BAD in AngII-stimulated VSMCs-Recently a growing list of biochemical pathways has been shown to be stimulated via 7TMRs through beta-arrestin-dependent mechanisms (2). These include the ERK1/2 MAPKs (21-26) and AKT (27). Because both ERK and AKT signaling are reported to exert cytoprotective actions, we examined their possible involvement in the anti-apoptotic effects of AngII on VSMCs. Here we demonstrate that in VSMCs stimulated with AngII, ERK1/2 are activated, and this is significantly reduced by siRNA-mediated knock-down of beta-arrestin-2 (Fig. 2, A-C). The reduction is observed only after a 2-min stimulation, suggesting that, as previously shown in HEK-293 cells (22), prior to that time activation proceeds exclusively through G protein-dependent mechanisms. Ribosomal S6 kinase (RSK) is a well known downstream kinase for ERK signaling and it mediates a variety of physiological responses including anti-apoptosis (40, 41). Furthermore, RSK is activated by phosphorylation in the cytoplasm (40, 41) where ERK activated by beta-arrestin-dependent mechanisms is confined (22, 26). Moreover, our recent high throughput proteomics screening using the stable isotope labeling amino acid in cell culture method have revealed that the level of p90RSK phosphorylation is increased by SII stimulation in HEK-293 cells expressing the AT1A receptor.3 Accordingly, we next tested whether phosphorylation of p90RSK occurs upon stimulation with AngII and whether this is mediated by beta-arrestin-2. As shown in Fig. 2, D and E, the kinetic pattern of AngII-stimulated p90RSK phosphorylation, particularly at ERK sites Thr359/Ser363 (40, 41), is similar to that for ERK activation. In control siRNA-transfected cells, p90RSK phosphorylation also reaches a maximal level at 5 min after stimulation although it lags slightly behind ERK activation (compare 2-min points in Fig. 2, C versus E) and decreases gradually over 20 min. Silencing beta-arrestin-2 expression leads to rapid and transient p90RSK phosphorylation, also similar to ERK activation. These results suggest that ERKs activated through both beta-arrestin-2- and G protein-dependent pathways can phosphorylate RSK. However, beta-arrestin-2-mediated phosphorylation of p90RSK is much slower and more prolonged than that due to activation of the beta-arrestin-2-independent pathway, which is presumably G-protein-mediated.
###end p 28
###begin p 29
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 299 302 299 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">113</sup>
###xml 453 454 450 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 494 495 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 500 501 497 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 486 501 483 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>F</italic> and <italic>G</italic></xref>
###xml 832 833 823 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
RSK is also known to have many downstream targets mediating numerous physiological responses (40, 41). One such target is the pro-apoptotic protein BAD and its phosphorylation by RSK is known to inhibit its pro-apoptotic functions (14-16). Accordingly, we next examined phosphorylation of BAD at Ser113 (known to be a preferred RSK site) in VSMCs. In these cells, beta-arrestin-2 RNA interference interestingly leads to almost complete attenuation in AT1R-mediated BAD phosphorylation (Fig. 2, F and G). Taken together, our results suggest that AngII-induced RSK phosphorylation by ERK is partially mediated by beta-arrestin-2- (especially >2 min) and G protein (<2 min)-dependent pathways. Nonetheless, it is predominantly RSK activated through the beta-arrestin-2-mediated pathway that phosphorylates BAD upon activation of the AT1 receptors in VSMCs.
###end p 29
###begin p 30
###xml 66 67 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 217 218 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 223 224 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 209 224 206 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>H</italic> and <italic>I</italic></xref>
To further validate the beta-arrestin-2-dependent nature of the AT1R-mediated activation of the ERK/p90RSK/BAD cascade, we stimulated the VSMCs with SII, which cannot activate G protein signaling. As shown in Fig. 2, H and I, SII stimulates both p90RSK and phosphorylation of BAD at the RSK site, thus confirming the G protein independence of these responses.
###end p 30
###begin p 31
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 227 229 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 314 315 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 417 420 414 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 463 464 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 469 470 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 455 470 452 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>J</italic> and <italic>K</italic></xref>
Another kinase that is known to phosphorylate and inactivate BAD leading to anti-apoptotic effects is AKT (17, 18). Moreover, beta-arrestin-mediated activation of AKT has been demonstrated for 7TM protease-activated receptors (27) as well as for the receptor tyrosine kinase insulin-like growth factor 1 receptor (6). Accordingly, we tested the ability of AngII to promote phosphorylation of the stimulatory site, Ser473, of AKT in the VSMCs. As shown in Fig. 2, J and K, time-dependent phosphorylation was observed, which was inhibited by beta-arrestin-2 siRNAs at times later than 2 min of stimulation, indicating that this process is mediated in part by beta-arrestin-2.
###end p 31
###begin p 32
###xml 0 96 0 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RSK- and AKT-mediated Phosphorylations of BAD Are Essential for AngII-stimulated Cell Protection</italic>
###xml 669 670 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 675 676 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 661 676 658 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>A</italic> and <italic>C</italic></xref>
###xml 706 707 703 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 700 707 697 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 716 717 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 710 717 707 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 818 821 815 818 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 888 891 885 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">113</sup>
RSK- and AKT-mediated Phosphorylations of BAD Are Essential for AngII-stimulated Cell Protection-Our data suggest that RSK- and/or AKT-mediated phosphorylation of BAD might be a molecular mechanism that is responsible for the beta-arrestin-2-mediated anti-apoptotic effects of AngII on VSMCs. To test this hypothesis, we first examined the effects of the RSK inhibitor SL0101 and the PI3K inhibitor LY294002, which is known to block AKT activation, on AngII-induced anti-apoptosis in VSMCs. Treatment with either SL0101 or LY294002 completely ablates the ability of AngII to protect against etoposide-induced apoptosis as assessed by either caspase-3 cleavage (Fig. 3, A and C) or DNA fragmentation (Fig. 3D). Fig. 3B shows that LY294002 blocks AngII-induced activation of AKT as assessed by phosphorylation of AKT Ser473, and SL0101 blocks phosphorylation of BAD at the RSK site, BAD Ser113. These results strongly support the thesis that beta-arrestin-2 mediates AngII-stimulated cell protection by regulating RSK- and AKT-mediated phosphorylation of BAD. Moreover the concerted activation of both pathways appears to be necessary because blockade of either alone completely eliminates the anti-apoptotic effect.
###end p 32
###begin p 33
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 600 607 600 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>E</italic></xref>
###xml 244 249 <span type="species:ncbi:10090">mouse</span>
To directly test whether RSK- and AKT-mediated phosphorylation of BAD are required for the anti-apoptotic actions of AngII, we studied the nature of overexpressed wild-type and phosphorylation-deficient mutants of BAD in VSMCs. We used the two mouse mutants BAD S112A and BAD S136A that are defective in RSK- and AKT-mediated phosphorylation, respectively (14, 18). Overexpression of wild-type BAD in the VSMCs leads to a typical apoptotic pattern of mitochondrial fragmentation as visualized by cytochrome c staining, whereas cells that do not express BAD show an intact mitochondrial architecture (Fig. 3E). Essentially identical images were obtained with the two mutant forms of BAD (supplemental Fig. S2), confirming the abilities of all these three forms of BAD to induce apoptosis upon overexpression.
###end p 33
###begin p 34
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 84 99 84 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>F</italic> and <italic>G</italic></xref>
###xml 255 256 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 247 262 247 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>F</italic> and <italic>G</italic></xref>
###xml 511 512 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 505 512 493 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>G</italic></xref>
###xml 767 768 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 769 770 754 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 759 770 744 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>A</italic>-<italic>D</italic></xref>
Next we examined caspase-3 activation in cells expressing the three BAD constructs (Fig. 3, F and G). Despite relatively inefficient (<10%) transfection of the cells, robust increases in the levels of cleaved caspase-3 were observed in all cases (Fig. 3, F and G). In this system, AngII stimulation leads to partial but significant (approximately30%) decreases in these levels in cells overexpressing the wild-type BAD, whereas such reductions are not observed in cells expressing BAD S112A or BAD S136A (Fig. 3G). These results support the conclusion that RSK- and AKT-mediated phosphorylation of BAD are required for AngII-stimulated, beta-arrestin-2-mediated cytoprotective processes. Furthermore, the results are consistent with the findings shown above (Fig. 3, A-D) that both activities of RSK and AKT are essential for AngII-stimulated protection from apoptotic stimuli.
###end p 34
###begin p 35
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 29 9 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of silencing</bold>
###xml 34 148 31 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-arrestin-2 expression on ERK-RSK-BAD phosphorylation as well as AKT activation in response to AngII in rat VSMCs.</bold>
###xml 148 151 145 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-G</italic>
###xml 258 259 243 244 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 357 358 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 391 392 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 408 411 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">359</sup>
###xml 415 418 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">363</sup>
###xml 420 421 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 438 441 414 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">113</sup>
###xml 443 444 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 481 483 457 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 486 487 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 544 555 520 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left panels</italic>
###xml 619 631 595 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panels</italic>
###xml 729 732 705 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTL</italic>
###xml 813 814 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 819 820 795 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 845 846 821 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 857 858 833 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 947 948 923 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1003 1004 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1009 1010 985 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1058 1059 1033 1034 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1232 1234 1207 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 1300 1301 1275 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1304 1305 1279 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 1310 1311 1285 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1386 1387 1361 1362 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1447 1450 1422 1425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 1467 1468 1442 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 1486 1487 1461 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1506 1507 1481 1482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 9 1690 9 1663 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><bold>Effects of silencing</bold> &#946;<bold>-arrestin-2 expression on ERK-RSK-BAD phosphorylation as well as AKT activation in response to AngII in rat VSMCs.</bold><italic>A-G</italic>, indicated siRNA-transfected VSMCs were serum-starved for &#8764;24 h and then stimulated with 100 n<sc>m</sc> AngII at 37 &#176;C for the indicated periods. After stimulation, expression of &#946;-arrestins (<italic>A</italic>) and phosphorylation of ERK1/2 (<italic>B</italic>), p90RSK at Thr<sup>359</sup>/Ser<sup>363</sup> (<italic>D</italic>), and BAD at Ser<sup>113</sup> (<italic>F</italic>) were visualized by immunoblotting (<italic>IB</italic>). <italic>C</italic>, contents of ERK1/2 phosphorylation in the immunoblots (<italic>left panels</italic>) were quantified and normalized by the amount of total ERK1/2 (<italic>right panels</italic>). Values were expressed as percent of the maximal phosphorylation of ERK1/2 obtained in control (<italic>CTL</italic>) siRNA-transfected cells. Data were obtained from five independent experiments. <italic>E</italic> and <italic>G</italic>, the amounts of p90RSK (<italic>E</italic>) and BAD (<italic>G</italic>) phosphorylation shown in the immunoblots were measured and determined as described for <italic>C</italic>. Data were obtained from six independent experiments. <italic>H</italic> and <italic>I</italic>, serum-starved VSMCs were stimulated with 10 &#956;<sc>m</sc> SII for 5 min. The level of SII-induced p90RSK and BAD phosphorylation were determined as described above and expressed folds over basal phosphorylation in non-stimulated (<italic>NS</italic>) cells. Values were obtained from seven independent experiments (<italic>I</italic>). <italic>J</italic> and <italic>K</italic>, siRNA-transfected VSMCs were serum-starved and then stimulated with 100 n<sc>m</sc> AngII for the indicated periods. AKT phosphorylation at Ser<sup>473</sup> was visualized (<italic>J</italic>) and determined (<italic>K</italic>) as described for <italic>C</italic> from six independent experiments. In all graphs, each data point represents the mean &#177; S.E., and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p>
###xml 9 1690 9 1663 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36"><bold>Effects of silencing</bold> &#946;<bold>-arrestin-2 expression on ERK-RSK-BAD phosphorylation as well as AKT activation in response to AngII in rat VSMCs.</bold><italic>A-G</italic>, indicated siRNA-transfected VSMCs were serum-starved for &#8764;24 h and then stimulated with 100 n<sc>m</sc> AngII at 37 &#176;C for the indicated periods. After stimulation, expression of &#946;-arrestins (<italic>A</italic>) and phosphorylation of ERK1/2 (<italic>B</italic>), p90RSK at Thr<sup>359</sup>/Ser<sup>363</sup> (<italic>D</italic>), and BAD at Ser<sup>113</sup> (<italic>F</italic>) were visualized by immunoblotting (<italic>IB</italic>). <italic>C</italic>, contents of ERK1/2 phosphorylation in the immunoblots (<italic>left panels</italic>) were quantified and normalized by the amount of total ERK1/2 (<italic>right panels</italic>). Values were expressed as percent of the maximal phosphorylation of ERK1/2 obtained in control (<italic>CTL</italic>) siRNA-transfected cells. Data were obtained from five independent experiments. <italic>E</italic> and <italic>G</italic>, the amounts of p90RSK (<italic>E</italic>) and BAD (<italic>G</italic>) phosphorylation shown in the immunoblots were measured and determined as described for <italic>C</italic>. Data were obtained from six independent experiments. <italic>H</italic> and <italic>I</italic>, serum-starved VSMCs were stimulated with 10 &#956;<sc>m</sc> SII for 5 min. The level of SII-induced p90RSK and BAD phosphorylation were determined as described above and expressed folds over basal phosphorylation in non-stimulated (<italic>NS</italic>) cells. Values were obtained from seven independent experiments (<italic>I</italic>). <italic>J</italic> and <italic>K</italic>, siRNA-transfected VSMCs were serum-starved and then stimulated with 100 n<sc>m</sc> AngII for the indicated periods. AKT phosphorylation at Ser<sup>473</sup> was visualized (<italic>J</italic>) and determined (<italic>K</italic>) as described for <italic>C</italic> from six independent experiments. In all graphs, each data point represents the mean &#177; S.E., and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p></caption>
###xml 1690 1690 1663 1663 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0170971160002"/>
###xml 0 1690 0 1663 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="36"><bold>Effects of silencing</bold> &#946;<bold>-arrestin-2 expression on ERK-RSK-BAD phosphorylation as well as AKT activation in response to AngII in rat VSMCs.</bold><italic>A-G</italic>, indicated siRNA-transfected VSMCs were serum-starved for &#8764;24 h and then stimulated with 100 n<sc>m</sc> AngII at 37 &#176;C for the indicated periods. After stimulation, expression of &#946;-arrestins (<italic>A</italic>) and phosphorylation of ERK1/2 (<italic>B</italic>), p90RSK at Thr<sup>359</sup>/Ser<sup>363</sup> (<italic>D</italic>), and BAD at Ser<sup>113</sup> (<italic>F</italic>) were visualized by immunoblotting (<italic>IB</italic>). <italic>C</italic>, contents of ERK1/2 phosphorylation in the immunoblots (<italic>left panels</italic>) were quantified and normalized by the amount of total ERK1/2 (<italic>right panels</italic>). Values were expressed as percent of the maximal phosphorylation of ERK1/2 obtained in control (<italic>CTL</italic>) siRNA-transfected cells. Data were obtained from five independent experiments. <italic>E</italic> and <italic>G</italic>, the amounts of p90RSK (<italic>E</italic>) and BAD (<italic>G</italic>) phosphorylation shown in the immunoblots were measured and determined as described for <italic>C</italic>. Data were obtained from six independent experiments. <italic>H</italic> and <italic>I</italic>, serum-starved VSMCs were stimulated with 10 &#956;<sc>m</sc> SII for 5 min. The level of SII-induced p90RSK and BAD phosphorylation were determined as described above and expressed folds over basal phosphorylation in non-stimulated (<italic>NS</italic>) cells. Values were obtained from seven independent experiments (<italic>I</italic>). <italic>J</italic> and <italic>K</italic>, siRNA-transfected VSMCs were serum-starved and then stimulated with 100 n<sc>m</sc> AngII for the indicated periods. AKT phosphorylation at Ser<sup>473</sup> was visualized (<italic>J</italic>) and determined (<italic>K</italic>) as described for <italic>C</italic> from six independent experiments. In all graphs, each data point represents the mean &#177; S.E., and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p></caption><graphic xlink:href="zbc0170971160002"/></fig>
###xml 138 141 <span type="species:ncbi:10116">rat</span>
FIGURE 2.Effects of silencing beta-arrestin-2 expression on ERK-RSK-BAD phosphorylation as well as AKT activation in response to AngII in rat VSMCs.A-G, indicated siRNA-transfected VSMCs were serum-starved for approximately24 h and then stimulated with 100 nm AngII at 37 degreesC for the indicated periods. After stimulation, expression of beta-arrestins (A) and phosphorylation of ERK1/2 (B), p90RSK at Thr359/Ser363 (D), and BAD at Ser113 (F) were visualized by immunoblotting (IB). C, contents of ERK1/2 phosphorylation in the immunoblots (left panels) were quantified and normalized by the amount of total ERK1/2 (right panels). Values were expressed as percent of the maximal phosphorylation of ERK1/2 obtained in control (CTL) siRNA-transfected cells. Data were obtained from five independent experiments. E and G, the amounts of p90RSK (E) and BAD (G) phosphorylation shown in the immunoblots were measured and determined as described for C. Data were obtained from six independent experiments. H and I, serum-starved VSMCs were stimulated with 10 mum SII for 5 min. The level of SII-induced p90RSK and BAD phosphorylation were determined as described above and expressed folds over basal phosphorylation in non-stimulated (NS) cells. Values were obtained from seven independent experiments (I). J and K, siRNA-transfected VSMCs were serum-starved and then stimulated with 100 nm AngII for the indicated periods. AKT phosphorylation at Ser473 was visualized (J) and determined (K) as described for C from six independent experiments. In all graphs, each data point represents the mean +/- S.E., and statistical analyses were carried out as described under "Experimental Procedures."
###end p 35
###begin p 36
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of silencing</bold>
###xml 25 139 22 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-arrestin-2 expression on ERK-RSK-BAD phosphorylation as well as AKT activation in response to AngII in rat VSMCs.</bold>
###xml 139 142 136 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-G</italic>
###xml 249 250 234 235 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 348 349 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 382 383 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 399 402 375 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">359</sup>
###xml 406 409 382 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">363</sup>
###xml 411 412 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 429 432 405 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">113</sup>
###xml 434 435 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 472 474 448 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 477 478 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 535 546 511 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left panels</italic>
###xml 610 622 586 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panels</italic>
###xml 720 723 696 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTL</italic>
###xml 804 805 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 810 811 786 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 836 837 812 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 848 849 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 938 939 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 994 995 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1000 1001 976 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1049 1050 1024 1025 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1223 1225 1198 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 1291 1292 1266 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1295 1296 1270 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 1301 1302 1276 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1377 1378 1352 1353 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1438 1441 1413 1416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 1458 1459 1433 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 1477 1478 1452 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1497 1498 1472 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 129 132 <span type="species:ncbi:10116">rat</span>
Effects of silencing beta-arrestin-2 expression on ERK-RSK-BAD phosphorylation as well as AKT activation in response to AngII in rat VSMCs.A-G, indicated siRNA-transfected VSMCs were serum-starved for approximately24 h and then stimulated with 100 nm AngII at 37 degreesC for the indicated periods. After stimulation, expression of beta-arrestins (A) and phosphorylation of ERK1/2 (B), p90RSK at Thr359/Ser363 (D), and BAD at Ser113 (F) were visualized by immunoblotting (IB). C, contents of ERK1/2 phosphorylation in the immunoblots (left panels) were quantified and normalized by the amount of total ERK1/2 (right panels). Values were expressed as percent of the maximal phosphorylation of ERK1/2 obtained in control (CTL) siRNA-transfected cells. Data were obtained from five independent experiments. E and G, the amounts of p90RSK (E) and BAD (G) phosphorylation shown in the immunoblots were measured and determined as described for C. Data were obtained from six independent experiments. H and I, serum-starved VSMCs were stimulated with 10 mum SII for 5 min. The level of SII-induced p90RSK and BAD phosphorylation were determined as described above and expressed folds over basal phosphorylation in non-stimulated (NS) cells. Values were obtained from seven independent experiments (I). J and K, siRNA-transfected VSMCs were serum-starved and then stimulated with 100 nm AngII for the indicated periods. AKT phosphorylation at Ser473 was visualized (J) and determined (K) as described for C from six independent experiments. In all graphs, each data point represents the mean +/- S.E., and statistical analyses were carried out as described under "Experimental Procedures."
###end p 36
###begin p 37
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 0 93 0 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">The AT<sub>1A</sub>R-stimulated ERK-RSK-BAD Phosphorylation Cascade in HEK-293 Cells Is Also Mediated by</italic>
###xml 98 109 95 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-2</italic>
###xml 297 299 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 301 303 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 359 361 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 797 799 791 793 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 993 994 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 995 996 989 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 985 996 979 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, <italic>A</italic>-<italic>C</italic></xref>
###xml 1066 1068 1060 1062 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1153 1156 1147 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">359</sup>
###xml 1160 1163 1154 1157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">363</sup>
###xml 1220 1221 1211 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1214 1221 1205 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1252 1253 1243 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1246 1253 1237 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1308 1309 1299 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1302 1309 1293 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 1478 1480 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 1482 1484 1473 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1544 1545 1535 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1538 1545 1529 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 1631 1634 1622 1625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">359</sup>
###xml 1642 1645 1633 1636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">363</sup>
###xml 1754 1755 1745 1746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1748 1755 1739 1746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 1932 1934 1920 1922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
The AT1AR-stimulated ERK-RSK-BAD Phosphorylation Cascade in HEK-293 Cells Is Also Mediated by beta-Arrestin-2-Phosphorylation of BAD is thought to control its apoptotic activity by regulating its functionally antagonistic binding to anti-apoptotic proteins such as Bcl-xL (dephosphorylated form) (11, 20) or the scaffold protein 14-3-3 (phosphorylated form) (19). Accordingly, we wished to determine the effects of beta-arrestin-2-mediated phosphorylation of BAD on its binding to Bcl-xL and 14-3-3. However, we were unable to detect the interaction of these proteins expressed at physiological levels in VSMCs with our co-immunoprecipitation assay. Alternatively, we found that we were able to perform such experiments with these proteins endogenously expressed in HEK-293 cells expressing the AT1A receptor. However, such experiments are only relevant to the situation in VSMCs if the signaling pathway we have identified in the VSMCs also operates in the HEK-293 cells. As shown in Fig. 4, A-C, in HEK-293 cells stably transfected with a plasmid expressing the AT1A receptor, AngII provokes a protracted activation (assessed by phosphorylation of Thr359/Ser363) of p90RSK. Two different beta-arrestin-2 siRNAs (Fig. 4A) inhibit this response (Fig. 4B), but only at times after 5 min of stimulation (Fig. 4C). In contrast, the protein kinase C (PKC) inhibitor Ro31-8425 or GF109203X, which has been shown in HEK-293 cells to block G protein-dependent ERK activation by AngII (21, 22), inhibits the early component of p90RSK activation (Fig. 4C). Confirming that virtually all of the AngII-induced phosphorylation of p90RSK at Thr359 and Ser363 is mediated by ERK, the MEK inhibitor U0126 completely abolishes the p90RSK phosphorylation response (Fig. 4C). These patterns of sensitivities to PKC blockade and beta-arrestin-2 siRNA directly parallel our previous findings for AngII-stimulated phosphorylation of ERK in these cells (22).
###end p 37
###begin p 38
###xml 161 162 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 167 168 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 153 168 150 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, <italic>D</italic> and <italic>E</italic></xref>
###xml 473 475 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">75</sup>
###xml 503 506 494 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink">113</sup>
###xml 529 530 520 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 535 536 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 521 536 512 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, <italic>D</italic> and <italic>E</italic></xref>
###xml 688 689 679 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 682 689 673 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 809 811 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 510 515 <span type="species:ncbi:9606">human</span>
Despite this evidence that beta-arrestin-2-mediated ERK activation accounts for only the later (>5 min) occurring phosphorylation of p90RSK, the data in Fig. 4, D and E, suggest that, as in the VSMCs, almost all of the downstream phosphorylation of BAD by RSK is mediated by the pool of p90RSK, which is activated through beta-arrestin-dependent ERK. After beta-arrestin-2 siRNA transfection, there is almost complete loss of the AngII-stimulated BAD phosphorylation at Ser75, the homologous site of Ser113 in human BAD (Fig. 4, D and E). As expected, virtually all the BAD phosphorylation at this site is also blocked by the selective RSK inhibitor SL0101 and MEK inhibitor U0126 (Fig. 4E). Because PKC inhibitors have been shown to efficiently block RSK, which belongs to the same AGC kinase family as PKC (42), their effects on BAD phosphorylation could not be reliably studied.
###end p 38
###begin p 39
###xml 140 142 140 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 174 189 174 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, <italic>F</italic> and <italic>G</italic></xref>
###xml 304 310 304 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 330 331 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 397 403 394 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 386 389 <span type="species:ncbi:10116">rat</span>
To further validate the G protein-independent nature of the phosphorylation of p90RSK and BAD, we stimulated HEK-293 cells expressing the AT1A receptor with SII. As shown in Fig. 4, F and G, this stimulation leads to prolonged increases in both p90RSK and BAD phosphorylation. Taken together, results in Fig. 4 confirm that the AT1R-beta-arrestin-2-ERK-p90RSK-BAD pathway delineated in rat VSMCs (Fig. 2) is also operative in HEK-293 cells.
###end p 39
###begin p 40
###xml 4 86 1 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-2 Regulates Interactions of BAD with Its Partners upon AngII Stimulation</italic>
###xml 197 199 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 201 203 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 205 207 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 339 340 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 338 340 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">2<italic>G</italic></xref>
###xml 346 347 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 345 347 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">4<italic>E</italic></xref>
###xml 447 448 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 441 448 432 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>K</italic></xref>
###xml 643 645 631 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 804 805 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 810 811 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 796 811 784 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>A</italic> and <italic>B</italic></xref>
###xml 911 913 899 901 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 943 944 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 949 950 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 935 950 923 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>C</italic> and <italic>D</italic></xref>
###xml 955 957 943 945 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1132 1135 1117 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-D</italic>
###xml 1124 1135 1109 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>A-D</italic></xref>
###xml 1236 1237 1221 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1242 1243 1227 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1228 1243 1213 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>E</italic> and <italic>F</italic></xref>
###xml 1429 1430 1411 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1435 1436 1417 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1421 1436 1403 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>G</italic> and <italic>H</italic></xref>
###xml 1560 1562 1542 1544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">75</sup>
###xml 1632 1633 1611 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1626 1633 1605 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 1698 1699 1677 1678 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
beta-Arrestin-2 Regulates Interactions of BAD with Its Partners upon AngII Stimulation-As noted above, the dynamic interactions of BAD with its partners regulate the pro-apoptotic function of BAD (11, 19, 20). Our results demonstrate that BAD phosphorylation by RSK is mediated predominantly by beta-arrestin-2-dependent signaling (Figs. 2G and 4E) and also suggest that its phosphorylation by AKT is partially dependent on beta-arrestin-2 (Fig. 2K). Accordingly, we examined BAD interactions with its partners at their endogenous levels upon AngII stimulation in control or beta-arrestin-2 siRNA-transfected HEK-293 cells stably expressing AT1A receptors. Stimulation with AngII leads to a significant increase in the amount of BAD present in 14-3-3 protein immunoprecipitates in control cells (Fig. 5, A and B). In parallel, the quantity of the 14-3-3 protein co-immunoprecipitated with BAD is augmented by AT1A receptor activation (Fig. 5, C and D). AT1AR-mediated increases in the interaction of BAD with 14-3-3 shown by both BAD and 14-3-3 immunoprecipitation are eliminated in beta-arrestin-2 siRNA-transfected cells (Fig. 5, A-D). Conversely, we found that AngII stimulation decreases the interaction of BAD with Bcl-xL. Fig. 5, E and F, show the reduced amount of Bcl-xL in BAD immunoprecipitates upon AngII stimulation in control cells. This reduction is not observed in beta-arrestin-2 siRNA-transfected cells. Fig. 5, G and H, show that in the HEK-293 cell lysates used in these experiments, AngII-stimulated BAD phosphorylation at the RSK site (Ser75) is completely abolished by beta-arrestin-2 siRNA, as shown in Fig. 4E. Taken together, these results demonstrate that activation of AT1 receptors leads to a beta-arrestin-2-dependent increase in BAD interaction with 14-3-3 and a decrease in its association with Bcl-xL, resulting in an anti-apoptotic signal. Moreover, the results strongly suggest that AngII-stimulated changes in BAD complex formation are mediated by p90RSK and AKT phosphorylation of BAD in a beta-arrestin-2-dependent manner.
###end p 40
###begin title 41
DISCUSSION
###end title 41
###begin p 42
###xml 928 929 913 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 930 932 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 1248 1249 1227 1228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
The present study shows that beta-arrestin-2 plays a crucial role in AngII-stimulated anti-apoptotic responses and delineates the downstream biochemical pathways responsible for this AngII-stimulated, beta-arrestin-2-mediated cytoprotection from apoptotic challenge. Upon stimulation with AngII, the pro-apoptotic protein BAD is phosphorylated through two signaling pathways, ERK-p90RSK and PI3K-AKT. Activation of both pathways appears to be beta-arrestin-2-dependent. This beta-arrestin-2-dependent BAD phosphorylation leads to increases in BAD-14-3-3 association and decreases in the interaction of BAD with Bcl-xL. Such changes in the association of BAD with its partners lead to attenuation of its pro-apoptotic function, resulting in AngII-stimulated protection from apoptotic challenges. There have been reports implicating beta-arrestins in both pro- and anti-apoptotic responses as well as in non-apoptotic cell death (3-10). However, the biochemical pathways through which beta-arrestins mediate these responses upon 7TMR activation have not been delineated. The results reported here establish a downstream molecular mechanism by which beta-arrestin-2 mediates anti-apoptosis in response to activation of the physiologically important AT1 receptor in a non-transfected natural cell, VSMC.
###end p 42
###begin p 43
###xml 177 178 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 180 182 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 183 185 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 205 207 199 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 443 444 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 446 448 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 629 631 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 803 805 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 807 809 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 1070 1071 1052 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 1073 1075 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1338 1339 1314 1315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1436 1438 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
beta-Arrestin-mediated, but G protein-independent, activation of ERK1/2 has been a focus of study for the functions of beta-arrestins as signal transducers for 7TMR activation (2, 21-25). In the case of AT1AR-mediated ERK activation, it has been demonstrated that upon activation of the receptor, beta-arrestin-2 scaffolds the components of the ERK cascade, Raf-1, MEK1, and ERK1/2, into the receptor complex, leading to activation of ERK1/2 (2, 43). In addition, we have previously shown that beta-arrestin-2-dependent activation displays distinct temporal and spatial patterns from those due to G protein-dependent activation (22). In particular, ERK activated via the beta-arrestin-2-dependent pathway is confined to the cytoplasm, whereas ERK activated via G proteins translocates into the nucleus (22, 26). These distinct patterns strongly suggest that the substrates of ERK activated via beta-arrestin-2-mediated signaling may be largely cytoplasmic. Cytoplasmic ERK activity appears to be important in the regulation of cell morphology, migration, and viability (2, 22). However, very little is known about how phosphorylation of cytoplasmic ERK substrates, downstream of beta-arrestin signaling, regulates cellular responses. The only known example is the very recent finding that beta-arrestin-2-mediated ERK activation by the AT1 receptor leads to an increase in protein synthesis via activation of a downstream kinase, Mnk1 (32). The present study reveals anti-apoptosis mediated by BAD phosphorylation as another downstream response of beta-arrestin-mediated ERK signaling stimulated by a 7TMR. These results thus expand our understanding of the roles of beta-arrestin in determining the physiological outcomes of signaling initiated from 7TMRs.
###end p 43
###begin p 44
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 143 9 143 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kinase activities of both RSK and AKT as well as BAD phosphorylation are required for AngII-promoted cellular protection in rat VSMCs.</bold>
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-D</italic>
###xml 201 202 200 201 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 225 226 223 224 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 324 325 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 330 331 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 389 390 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 447 448 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 480 486 472 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 581 585 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO</italic>
###xml 729 730 719 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 733 734 723 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 805 808 795 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 823 826 813 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink">113</sup>
###xml 862 864 852 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 867 868 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 940 941 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1012 1015 1000 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E-G</italic>
###xml 1137 1138 1125 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1169 1170 1156 1157 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1270 1271 1257 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1273 1278 1260 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1324 1327 1311 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1447 1448 1434 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1520 1521 1507 1508 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1627 1628 1614 1615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 9 1891 9 1876 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45"><bold>Kinase activities of both RSK and AKT as well as BAD phosphorylation are required for AngII-promoted cellular protection in rat VSMCs.</bold><italic>A-D</italic>, serum-starved VSMCs were incubated with either 100 &#956;<sc>m</sc> SL0101 for 2 h or 1 &#956;<sc>m</sc> LY294004 for 1 h at 37 &#176;C before stimulation with AngII and following etoposide treatment. <italic>A</italic> and <italic>C</italic>, contents of pro- and cleaved caspase-3 were visualized (<italic>A</italic>), and the amounts of cleaved caspase-3 were determined (<italic>C</italic>) as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. Values were expressed as percent of the level obtained in vehicle alone (dimethyl sulfoxide, <italic>DMSO</italic>) and then etoposide-treated cells in the absence of stimulation with AngII and represent the mean &#177; S.E. from seven independent experiments (<italic>C</italic>). <italic>B</italic>, after stimulation with AngII for 5 min, phosphorylation of AKT at Ser<sup>473</sup> and BAD at Ser<sup>113</sup> were visualized by immunoblotting (<italic>IB</italic>). <italic>D</italic>, levels of fragmented DNA were measured and expressed as described for <italic>C</italic>. Data represent the mean &#177; S.E. from seven independent experiments. <italic>E-G</italic>, VSMCs were transfected with each plasmid expressing the indicated BAD. Empty pcDNA3 was used as a transfection control. <italic>E</italic>, cells were treated with 50 &#956;<sc>m</sc> Z-VAD-fmk during transfection. Within 24 h after transfection, cellular distribution of cytochrome <italic>c</italic> (<italic>green</italic>) and expression of hemagglutinin-tagged BAD (<italic>red</italic>) were visualized by immunostaining. Images shown represent similar results obtained from four independent experiments. <italic>F</italic>, approximately 6 h after transfection, cells were stimulated with 300 n<sc>m</sc> AngII and incubated overnight. Contents of pro- and cleaved caspase-3 were visualized by immunoblotting. <italic>G</italic>, the amounts of cleaved caspase-3 were measured and expressed as percent of the maximum level obtained from each 10 independent experiment. Values represent the mean &#177; S.E. All statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p>
###xml 9 1891 9 1876 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45"><bold>Kinase activities of both RSK and AKT as well as BAD phosphorylation are required for AngII-promoted cellular protection in rat VSMCs.</bold><italic>A-D</italic>, serum-starved VSMCs were incubated with either 100 &#956;<sc>m</sc> SL0101 for 2 h or 1 &#956;<sc>m</sc> LY294004 for 1 h at 37 &#176;C before stimulation with AngII and following etoposide treatment. <italic>A</italic> and <italic>C</italic>, contents of pro- and cleaved caspase-3 were visualized (<italic>A</italic>), and the amounts of cleaved caspase-3 were determined (<italic>C</italic>) as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. Values were expressed as percent of the level obtained in vehicle alone (dimethyl sulfoxide, <italic>DMSO</italic>) and then etoposide-treated cells in the absence of stimulation with AngII and represent the mean &#177; S.E. from seven independent experiments (<italic>C</italic>). <italic>B</italic>, after stimulation with AngII for 5 min, phosphorylation of AKT at Ser<sup>473</sup> and BAD at Ser<sup>113</sup> were visualized by immunoblotting (<italic>IB</italic>). <italic>D</italic>, levels of fragmented DNA were measured and expressed as described for <italic>C</italic>. Data represent the mean &#177; S.E. from seven independent experiments. <italic>E-G</italic>, VSMCs were transfected with each plasmid expressing the indicated BAD. Empty pcDNA3 was used as a transfection control. <italic>E</italic>, cells were treated with 50 &#956;<sc>m</sc> Z-VAD-fmk during transfection. Within 24 h after transfection, cellular distribution of cytochrome <italic>c</italic> (<italic>green</italic>) and expression of hemagglutinin-tagged BAD (<italic>red</italic>) were visualized by immunostaining. Images shown represent similar results obtained from four independent experiments. <italic>F</italic>, approximately 6 h after transfection, cells were stimulated with 300 n<sc>m</sc> AngII and incubated overnight. Contents of pro- and cleaved caspase-3 were visualized by immunoblotting. <italic>G</italic>, the amounts of cleaved caspase-3 were measured and expressed as percent of the maximum level obtained from each 10 independent experiment. Values represent the mean &#177; S.E. All statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p></caption>
###xml 1891 1891 1876 1876 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0170971160003"/>
###xml 0 1891 0 1876 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="45"><bold>Kinase activities of both RSK and AKT as well as BAD phosphorylation are required for AngII-promoted cellular protection in rat VSMCs.</bold><italic>A-D</italic>, serum-starved VSMCs were incubated with either 100 &#956;<sc>m</sc> SL0101 for 2 h or 1 &#956;<sc>m</sc> LY294004 for 1 h at 37 &#176;C before stimulation with AngII and following etoposide treatment. <italic>A</italic> and <italic>C</italic>, contents of pro- and cleaved caspase-3 were visualized (<italic>A</italic>), and the amounts of cleaved caspase-3 were determined (<italic>C</italic>) as described in the legend to <xref rid="fig1" ref-type="fig">Fig. 1</xref>. Values were expressed as percent of the level obtained in vehicle alone (dimethyl sulfoxide, <italic>DMSO</italic>) and then etoposide-treated cells in the absence of stimulation with AngII and represent the mean &#177; S.E. from seven independent experiments (<italic>C</italic>). <italic>B</italic>, after stimulation with AngII for 5 min, phosphorylation of AKT at Ser<sup>473</sup> and BAD at Ser<sup>113</sup> were visualized by immunoblotting (<italic>IB</italic>). <italic>D</italic>, levels of fragmented DNA were measured and expressed as described for <italic>C</italic>. Data represent the mean &#177; S.E. from seven independent experiments. <italic>E-G</italic>, VSMCs were transfected with each plasmid expressing the indicated BAD. Empty pcDNA3 was used as a transfection control. <italic>E</italic>, cells were treated with 50 &#956;<sc>m</sc> Z-VAD-fmk during transfection. Within 24 h after transfection, cellular distribution of cytochrome <italic>c</italic> (<italic>green</italic>) and expression of hemagglutinin-tagged BAD (<italic>red</italic>) were visualized by immunostaining. Images shown represent similar results obtained from four independent experiments. <italic>F</italic>, approximately 6 h after transfection, cells were stimulated with 300 n<sc>m</sc> AngII and incubated overnight. Contents of pro- and cleaved caspase-3 were visualized by immunoblotting. <italic>G</italic>, the amounts of cleaved caspase-3 were measured and expressed as percent of the maximum level obtained from each 10 independent experiment. Values represent the mean &#177; S.E. All statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p></caption><graphic xlink:href="zbc0170971160003"/></fig>
###xml 133 136 <span type="species:ncbi:10116">rat</span>
FIGURE 3.Kinase activities of both RSK and AKT as well as BAD phosphorylation are required for AngII-promoted cellular protection in rat VSMCs.A-D, serum-starved VSMCs were incubated with either 100 mum SL0101 for 2 h or 1 mum LY294004 for 1 h at 37 degreesC before stimulation with AngII and following etoposide treatment. A and C, contents of pro- and cleaved caspase-3 were visualized (A), and the amounts of cleaved caspase-3 were determined (C) as described in the legend to Fig. 1. Values were expressed as percent of the level obtained in vehicle alone (dimethyl sulfoxide, DMSO) and then etoposide-treated cells in the absence of stimulation with AngII and represent the mean +/- S.E. from seven independent experiments (C). B, after stimulation with AngII for 5 min, phosphorylation of AKT at Ser473 and BAD at Ser113 were visualized by immunoblotting (IB). D, levels of fragmented DNA were measured and expressed as described for C. Data represent the mean +/- S.E. from seven independent experiments. E-G, VSMCs were transfected with each plasmid expressing the indicated BAD. Empty pcDNA3 was used as a transfection control. E, cells were treated with 50 mum Z-VAD-fmk during transfection. Within 24 h after transfection, cellular distribution of cytochrome c (green) and expression of hemagglutinin-tagged BAD (red) were visualized by immunostaining. Images shown represent similar results obtained from four independent experiments. F, approximately 6 h after transfection, cells were stimulated with 300 nm AngII and incubated overnight. Contents of pro- and cleaved caspase-3 were visualized by immunoblotting. G, the amounts of cleaved caspase-3 were measured and expressed as percent of the maximum level obtained from each 10 independent experiment. Values represent the mean +/- S.E. All statistical analyses were carried out as described under "Experimental Procedures."
###end p 44
###begin p 45
###xml 0 134 0 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kinase activities of both RSK and AKT as well as BAD phosphorylation are required for AngII-promoted cellular protection in rat VSMCs.</bold>
###xml 134 137 134 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-D</italic>
###xml 192 193 191 192 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 216 217 214 215 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 315 316 307 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 321 322 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 380 381 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 438 439 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 471 477 463 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 572 576 564 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO</italic>
###xml 720 721 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 724 725 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 796 799 786 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 814 817 804 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink">113</sup>
###xml 853 855 843 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 858 859 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 931 932 921 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1003 1006 991 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E-G</italic>
###xml 1128 1129 1116 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1160 1161 1147 1148 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1261 1262 1248 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1264 1269 1251 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1315 1318 1302 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1438 1439 1425 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1511 1512 1498 1499 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1618 1619 1605 1606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 124 127 <span type="species:ncbi:10116">rat</span>
Kinase activities of both RSK and AKT as well as BAD phosphorylation are required for AngII-promoted cellular protection in rat VSMCs.A-D, serum-starved VSMCs were incubated with either 100 mum SL0101 for 2 h or 1 mum LY294004 for 1 h at 37 degreesC before stimulation with AngII and following etoposide treatment. A and C, contents of pro- and cleaved caspase-3 were visualized (A), and the amounts of cleaved caspase-3 were determined (C) as described in the legend to Fig. 1. Values were expressed as percent of the level obtained in vehicle alone (dimethyl sulfoxide, DMSO) and then etoposide-treated cells in the absence of stimulation with AngII and represent the mean +/- S.E. from seven independent experiments (C). B, after stimulation with AngII for 5 min, phosphorylation of AKT at Ser473 and BAD at Ser113 were visualized by immunoblotting (IB). D, levels of fragmented DNA were measured and expressed as described for C. Data represent the mean +/- S.E. from seven independent experiments. E-G, VSMCs were transfected with each plasmid expressing the indicated BAD. Empty pcDNA3 was used as a transfection control. E, cells were treated with 50 mum Z-VAD-fmk during transfection. Within 24 h after transfection, cellular distribution of cytochrome c (green) and expression of hemagglutinin-tagged BAD (red) were visualized by immunostaining. Images shown represent similar results obtained from four independent experiments. F, approximately 6 h after transfection, cells were stimulated with 300 nm AngII and incubated overnight. Contents of pro- and cleaved caspase-3 were visualized by immunoblotting. G, the amounts of cleaved caspase-3 were measured and expressed as percent of the maximum level obtained from each 10 independent experiment. Values represent the mean +/- S.E. All statistical analyses were carried out as described under "Experimental Procedures."
###end p 45
###begin p 46
###xml 188 189 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 512 513 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 673 675 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 769 770 760 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 851 852 839 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 857 858 845 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 843 858 831 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>J</italic> and <italic>K</italic></xref>
###xml 1033 1034 1021 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1039 1040 1027 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1025 1040 1013 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>C</italic> and <italic>D</italic></xref>
###xml 483 488 <span type="species:ncbi:10090">mouse</span>
Besides ERK1/2, beta-arrestins have been implicated in the regulation of various other signaling molecules. These include other MAPKs, JNK3, and p38 as well as c-Src, PI3K, AKT, and RhoA (2). Most of these molecules have been shown to be involved in regulation of apoptosis. In the case of AKT for example, it has been reported that deficiency of beta-arrestins 1 and 2 leads to loss of AKT activation and anti-apoptotic effects following insulin-like growth factor 1 stimulation in mouse embryonic fibroblasts (6). Although there has been a report showing beta-arrestin-1-dependent AKT activation in response to thrombin mediated through 7TM protease-activated receptors (27), its function in apoptosis was not studied. Our present data show that stimulation of the AT1 receptor leads to AKT activation in a beta-arrestin-2-dependent manner (Fig. 2, J and K). Our results also demonstrate that the activity of PI3K, the upstream kinase of AKT, is required for AngII-stimulated protection from apoptotic challenges in VSMCs (Fig. 3, C and D). As described above, beta-arrestin might regulate apoptotic processes through multiple mechanisms. In fact, the present study indicates that beta-arrestin-2 mediates the anti-apoptotic response to AngII through two different pathways, ERK-RSK and PI3K-AKT.
###end p 46
###begin p 47
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 105 107 102 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 13 151 10 148 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-2 also mediates the ERK-RSK-BAD phosphorylation cascade upon stimulation of the AT<sub>1A</sub> receptor stably expressed in HEK-293 cells.</bold>
###xml 151 154 148 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-E</italic>
###xml 316 317 300 301 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 335 336 318 319 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 348 351 331 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFX</italic>
###xml 362 363 344 345 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 388 389 369 370 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 434 435 415 416 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 558 559 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 597 600 569 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">359</sup>
###xml 604 607 576 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">363</sup>
###xml 609 610 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 626 628 598 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">75</sup>
###xml 630 631 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 652 654 624 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 675 676 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 687 688 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 754 760 726 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 829 832 801 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTL</italic>
###xml 923 924 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 929 930 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 948 950 920 922 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 1003 1004 974 975 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1056 1066 1027 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left panel</italic>
###xml 1077 1088 1048 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panel</italic>
###xml 1123 1124 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1142 1143 1113 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1291 1292 1262 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 9 1442 9 1411 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">&#946;<bold>-Arrestin-2 also mediates the ERK-RSK-BAD phosphorylation cascade upon stimulation of the AT<sub>1A</sub> receptor stably expressed in HEK-293 cells.</bold><italic>A-E</italic>, cells were transfected with the indicated siRNAs and serum starved for &#8764;6 h. During starvation, inhibitors were pre-treated before stimulation: 1 &#956;<sc>m</sc> Ro31-8425, 2.5 &#956;<sc>m</sc> GF109203X (<italic>GFX</italic>), and 5 &#956;<sc>m</sc> U0126 for 30 min; 100 &#956;<sc>m</sc> SL0101 for 2 h. After stimulation with 100 n<sc>m</sc> AngII at 37 &#176;C for the indicated periods, whole cell extracts were prepared to visualize expression &#946;-arrestins (<italic>A</italic>) and phosphorylation of p90RSK at Thr<sup>359</sup>/Ser<sup>363</sup> (<italic>B</italic>) and BAD at Ser<sup>75</sup> (<italic>D</italic>) by immunoblotting (<italic>IB</italic>). Levels of p90RSK (<italic>C</italic>) and BAD (<italic>D</italic>) phosphorylation in each sample were determined as described for <xref rid="fig2" ref-type="fig">Fig. 2</xref> and expressed as percent of the maximal phosphorylation in control (<italic>CTL</italic>) siRNA-transfected cells. Data were obtained from at least three independent experiments. <italic>F</italic> and <italic>G</italic>, serum-starved AT<sub>1A</sub>R-expressing HEK-293 cells were stimulated with 10 &#956;<sc>m</sc> SII for the indicated periods. Contents of p90RSK (<italic>left panel</italic>) and BAD (<italic>right panel</italic>) phosphorylation were visualized (<italic>F</italic>) and determined (<italic>G</italic>). Levels of phosphorylation in each time point were expressed as percent of the maximal phosphorylation obtained in three independent experiments (<italic>G</italic>). In all graphs, each data point represents the mean &#177; S.E. and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p>
###xml 9 1442 9 1411 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">&#946;<bold>-Arrestin-2 also mediates the ERK-RSK-BAD phosphorylation cascade upon stimulation of the AT<sub>1A</sub> receptor stably expressed in HEK-293 cells.</bold><italic>A-E</italic>, cells were transfected with the indicated siRNAs and serum starved for &#8764;6 h. During starvation, inhibitors were pre-treated before stimulation: 1 &#956;<sc>m</sc> Ro31-8425, 2.5 &#956;<sc>m</sc> GF109203X (<italic>GFX</italic>), and 5 &#956;<sc>m</sc> U0126 for 30 min; 100 &#956;<sc>m</sc> SL0101 for 2 h. After stimulation with 100 n<sc>m</sc> AngII at 37 &#176;C for the indicated periods, whole cell extracts were prepared to visualize expression &#946;-arrestins (<italic>A</italic>) and phosphorylation of p90RSK at Thr<sup>359</sup>/Ser<sup>363</sup> (<italic>B</italic>) and BAD at Ser<sup>75</sup> (<italic>D</italic>) by immunoblotting (<italic>IB</italic>). Levels of p90RSK (<italic>C</italic>) and BAD (<italic>D</italic>) phosphorylation in each sample were determined as described for <xref rid="fig2" ref-type="fig">Fig. 2</xref> and expressed as percent of the maximal phosphorylation in control (<italic>CTL</italic>) siRNA-transfected cells. Data were obtained from at least three independent experiments. <italic>F</italic> and <italic>G</italic>, serum-starved AT<sub>1A</sub>R-expressing HEK-293 cells were stimulated with 10 &#956;<sc>m</sc> SII for the indicated periods. Contents of p90RSK (<italic>left panel</italic>) and BAD (<italic>right panel</italic>) phosphorylation were visualized (<italic>F</italic>) and determined (<italic>G</italic>). Levels of phosphorylation in each time point were expressed as percent of the maximal phosphorylation obtained in three independent experiments (<italic>G</italic>). In all graphs, each data point represents the mean &#177; S.E. and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p></caption>
###xml 1442 1442 1411 1411 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0170971160004"/>
###xml 0 1442 0 1411 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="48">&#946;<bold>-Arrestin-2 also mediates the ERK-RSK-BAD phosphorylation cascade upon stimulation of the AT<sub>1A</sub> receptor stably expressed in HEK-293 cells.</bold><italic>A-E</italic>, cells were transfected with the indicated siRNAs and serum starved for &#8764;6 h. During starvation, inhibitors were pre-treated before stimulation: 1 &#956;<sc>m</sc> Ro31-8425, 2.5 &#956;<sc>m</sc> GF109203X (<italic>GFX</italic>), and 5 &#956;<sc>m</sc> U0126 for 30 min; 100 &#956;<sc>m</sc> SL0101 for 2 h. After stimulation with 100 n<sc>m</sc> AngII at 37 &#176;C for the indicated periods, whole cell extracts were prepared to visualize expression &#946;-arrestins (<italic>A</italic>) and phosphorylation of p90RSK at Thr<sup>359</sup>/Ser<sup>363</sup> (<italic>B</italic>) and BAD at Ser<sup>75</sup> (<italic>D</italic>) by immunoblotting (<italic>IB</italic>). Levels of p90RSK (<italic>C</italic>) and BAD (<italic>D</italic>) phosphorylation in each sample were determined as described for <xref rid="fig2" ref-type="fig">Fig. 2</xref> and expressed as percent of the maximal phosphorylation in control (<italic>CTL</italic>) siRNA-transfected cells. Data were obtained from at least three independent experiments. <italic>F</italic> and <italic>G</italic>, serum-starved AT<sub>1A</sub>R-expressing HEK-293 cells were stimulated with 10 &#956;<sc>m</sc> SII for the indicated periods. Contents of p90RSK (<italic>left panel</italic>) and BAD (<italic>right panel</italic>) phosphorylation were visualized (<italic>F</italic>) and determined (<italic>G</italic>). Levels of phosphorylation in each time point were expressed as percent of the maximal phosphorylation obtained in three independent experiments (<italic>G</italic>). In all graphs, each data point represents the mean &#177; S.E. and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p></caption><graphic xlink:href="zbc0170971160004"/></fig>
FIGURE 4.beta-Arrestin-2 also mediates the ERK-RSK-BAD phosphorylation cascade upon stimulation of the AT1A receptor stably expressed in HEK-293 cells.A-E, cells were transfected with the indicated siRNAs and serum starved for approximately6 h. During starvation, inhibitors were pre-treated before stimulation: 1 mum Ro31-8425, 2.5 mum GF109203X (GFX), and 5 mum U0126 for 30 min; 100 mum SL0101 for 2 h. After stimulation with 100 nm AngII at 37 degreesC for the indicated periods, whole cell extracts were prepared to visualize expression beta-arrestins (A) and phosphorylation of p90RSK at Thr359/Ser363 (B) and BAD at Ser75 (D) by immunoblotting (IB). Levels of p90RSK (C) and BAD (D) phosphorylation in each sample were determined as described for Fig. 2 and expressed as percent of the maximal phosphorylation in control (CTL) siRNA-transfected cells. Data were obtained from at least three independent experiments. F and G, serum-starved AT1AR-expressing HEK-293 cells were stimulated with 10 mum SII for the indicated periods. Contents of p90RSK (left panel) and BAD (right panel) phosphorylation were visualized (F) and determined (G). Levels of phosphorylation in each time point were expressed as percent of the maximal phosphorylation obtained in three independent experiments (G). In all graphs, each data point represents the mean +/- S.E. and statistical analyses were carried out as described under "Experimental Procedures."
###end p 47
###begin p 48
###xml 96 98 93 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 4 142 1 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-Arrestin-2 also mediates the ERK-RSK-BAD phosphorylation cascade upon stimulation of the AT<sub>1A</sub> receptor stably expressed in HEK-293 cells.</bold>
###xml 142 145 139 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-E</italic>
###xml 307 308 291 292 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 326 327 309 310 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 339 342 322 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFX</italic>
###xml 353 354 335 336 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 379 380 360 361 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 425 426 406 407 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 549 550 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 588 591 560 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">359</sup>
###xml 595 598 567 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">363</sup>
###xml 600 601 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 617 619 589 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">75</sup>
###xml 621 622 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 643 645 615 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 666 667 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 678 679 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 745 751 717 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 820 823 792 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTL</italic>
###xml 914 915 886 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 920 921 892 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 939 941 911 913 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 994 995 965 966 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1047 1057 1018 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left panel</italic>
###xml 1068 1079 1039 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panel</italic>
###xml 1114 1115 1085 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1133 1134 1104 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1282 1283 1253 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
beta-Arrestin-2 also mediates the ERK-RSK-BAD phosphorylation cascade upon stimulation of the AT1A receptor stably expressed in HEK-293 cells.A-E, cells were transfected with the indicated siRNAs and serum starved for approximately6 h. During starvation, inhibitors were pre-treated before stimulation: 1 mum Ro31-8425, 2.5 mum GF109203X (GFX), and 5 mum U0126 for 30 min; 100 mum SL0101 for 2 h. After stimulation with 100 nm AngII at 37 degreesC for the indicated periods, whole cell extracts were prepared to visualize expression beta-arrestins (A) and phosphorylation of p90RSK at Thr359/Ser363 (B) and BAD at Ser75 (D) by immunoblotting (IB). Levels of p90RSK (C) and BAD (D) phosphorylation in each sample were determined as described for Fig. 2 and expressed as percent of the maximal phosphorylation in control (CTL) siRNA-transfected cells. Data were obtained from at least three independent experiments. F and G, serum-starved AT1AR-expressing HEK-293 cells were stimulated with 10 mum SII for the indicated periods. Contents of p90RSK (left panel) and BAD (right panel) phosphorylation were visualized (F) and determined (G). Levels of phosphorylation in each time point were expressed as percent of the maximal phosphorylation obtained in three independent experiments (G). In all graphs, each data point represents the mean +/- S.E. and statistical analyses were carried out as described under "Experimental Procedures."
###end p 48
###begin p 49
###xml 139 140 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 321 323 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 325 327 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 419 421 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 422 424 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 534 536 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 538 540 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 542 544 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref44">44</xref>
###xml 723 724 720 721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 742 743 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 741 743 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">3<italic>B</italic></xref>
###xml 749 750 746 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 748 750 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">4<italic>E</italic></xref>
###xml 814 817 811 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">113</sup>
###xml 835 836 832 833 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1047 1048 1044 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1053 1054 1050 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1039 1054 1036 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>C</italic> and <italic>D</italic></xref>
###xml 1181 1185 1178 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 1189 1192 1186 1189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">136</sup>
###xml 1194 1196 1191 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 1198 1200 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 1248 1250 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref45">45</xref>
###xml 409 412 <span type="species:ncbi:10116">rat</span>
We show that p90RSK is a kinase that transfers the beta-arrestin-mediated ERK activation signal to anti-apoptotic effects in response to AT1 receptor activation. RSK is a well known ERK substrate and mediates signals to many cellular responses, including cell survival, through phosphorylation of its downstream targets (40, 41). One such target is BAD, which RSK phosphorylates at serine 113 (in the case of rat BAD) (14-16). In addition to RSK, PKA and AKT have been considered as putative upstream kinases for BAD phosphorylation (16, 17, 44). Nonetheless, our data show that inhibition of either ERK or RSK, but not PI3K activities completely abolishes phosphorylation of BAD at this site following activation of the AT1 receptor (Figs. 3B and 4E). Such data clearly demonstrate that BAD phosphorylation at Ser113 in response to AT1 receptor activation is mediated through the ERK-RSK pathway. In addition to the ERK-RSK-BAD pathway, our data show that blockade of the PI3K-AKT pathway also eliminates AngII-stimulated anti-apoptosis (Fig. 3, C and D). However, this PI3K/AKT-dependent anti-apoptotic effect must be mediated through phosphorylation of BAD at a different site, e.g. Ser136 (17, 18) or possibly phosphorylation of other targets (45).
###end p 49
###begin p 50
###xml 147 148 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 179 180 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 185 186 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 176 186 173 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">2, <italic>F</italic> and <italic>G</italic></xref>
###xml 195 196 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 201 202 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 192 202 189 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">4, <italic>D</italic> and <italic>E</italic></xref>
###xml 413 414 407 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 516 518 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 520 522 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 711 712 702 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 717 718 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 708 718 699 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">2, <italic>D</italic> and <italic>E</italic></xref>
###xml 727 728 718 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 733 734 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 724 734 715 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">4, <italic>B</italic> and <italic>C</italic></xref>
###xml 928 930 916 918 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 941 943 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 945 947 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1032 1034 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref46">46</xref>
###xml 1036 1038 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 1228 1229 1216 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1234 1235 1222 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1225 1235 1213 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">2, <italic>H</italic> and <italic>I</italic></xref>
###xml 1244 1245 1232 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1250 1251 1238 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1241 1251 1229 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">4, <italic>F</italic> and <italic>G</italic></xref>
###xml 1305 1306 1293 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1307 1308 1295 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J</italic>
###xml 1297 1308 1285 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>H</italic>-<italic>J</italic></xref>
###xml 1356 1357 1344 1345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1581 1583 1569 1571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 1688 1690 1673 1675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1692 1694 1677 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 1713 1714 1698 1699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1846 1852 1828 1834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
Our data show that knocking-down beta-arrestin-2 expression leads to almost complete inhibition in RSK-mediated phosphorylation of BAD following AT1 receptor activation (Figs. 2, F and G, and 4, D and E), suggesting that this process may be entirely beta-arrestin-2-mediated. These results are quite interesting in view of the previous and present findings that ERK activation in response to stimulation of the AT1 receptor is mediated both by independent beta-arrestin-2- and G protein-mediated signaling pathways (21, 22). The data presented here also show that activation of p90RSK, the kinase that transfers signals from activated ERK to BAD phosphorylation, is mediated through these two pathways (Fig. 2, D and E, and 4, B and C). Furthermore, we have previously demonstrated that PKC activity is essential for G protein-dependent, but not beta-arrestin-mediated signaling to ERK activation following stimulation of the AT1A receptor (21, 22). There have been reports that PKC is involved in RSK-mediated BAD phosphorylation (46, 47), implying that G protein-dependent signaling might be involved. However, we found that SII, a mutant ligand that fails to activate G proteins, induces BAD phosphorylation by RSK (Figs. 2, H and I, and 4, F and G) as well as promotes anti-apoptotic effects (Fig. 1, H-J). This strongly supports the contention that AT1R-mediated BAD phosphorylation via the ERK-RSK pathway in VSMCs as well as HEK-293 cells is G protein-independent. Furthermore, we have previously shown that restriction of activated ERK to the cytoplasm, where BAD resides (13), is one of the striking characteristics of beta-arrestin-, but not G protein-dependent ERK activation (22, 26). Consequently, AT1R-induced phosphorylation of BAD by RSK provides an example of how an appreciation of the distinct characteristics of beta-arrestin versus G protein signaling can illuminate issues of apparent "compartmentalization" of cellular signaling events.
###end p 50
###begin p 51
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 19 9 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of</bold>
###xml 109 111 106 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 24 145 21 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-arrestin-2 knocking down on AngII-induced interaction of BAD with its partners in AT<sub>1A</sub>R-stably expressing HEK-293 cells.</bold>
###xml 190 193 187 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTL</italic>
###xml 219 223 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arr2</italic>
###xml 328 329 307 308 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 348 349 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 412 414 391 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IP</italic>
###xml 524 526 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 529 539 508 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper blot</italic>
###xml 642 652 621 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower blot</italic>
###xml 655 656 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 738 740 717 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 826 829 805 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C-F</italic>
###xml 908 909 887 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 923 924 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1012 1016 991 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. D</italic>
###xml 1117 1118 1096 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1220 1221 1199 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1226 1227 1205 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1258 1260 1237 1239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">75</sup>
###xml 1334 1335 1313 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1351 1352 1330 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1490 1491 1469 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 9 1632 9 1609 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52"><bold>Effects of</bold> &#946;<bold>-arrestin-2 knocking down on AngII-induced interaction of BAD with its partners in AT<sub>1A</sub>R-stably expressing HEK-293 cells.</bold> Cells were transfected with either control (<italic>CTL</italic>) or &#946;-arrestin-2 (&#946;<italic>arr2</italic>) siRNA. After transfection, cells were serum-starved for &#8764;6 h and then stimulated with 100 n<sc>m</sc> AngII for 30 min. <italic>A</italic>, cell lysates were prepared and used for immunoprecipitation (<italic>IP</italic>) with a 14-3-3 antibody. The BAD protein co-immunoprecipitated with 14-3-3 was visualized by immunoblotting (<italic>IB</italic>) (<italic>upper blot</italic>), and its amount in each sample was quantified and normalized by the amounts of BAD in input lysates (<italic>lower blot</italic>). <italic>B</italic>, values were expressed as folds over the basal level obtained in non-stimulated (<italic>NS</italic>), CTL siRNA-transfected cells. Data were obtained from four independent experiments. <italic>C-F</italic>, after immunoprecipitation with a BAD antibody, co-immunoprecipitated 14-3-3 (<italic>C</italic>) and Bcl-xL (<italic>E</italic>) proteins with BAD were visualized, and their amounts were determined as described for <italic>A. D</italic>, data were expressed as folds over the basal level and obtained from three independent experiments. <italic>F</italic>, values were expressed as percent of the basal level and obtained from four independent experiments. <italic>G</italic> and <italic>H</italic>, phosphorylation of BAD at Ser<sup>75</sup> in each lysate used for immunoprecipitation experiments were visualized (<italic>G</italic>) and measured (<italic>H</italic>). Data were expressed as percent of the response to AngII in CTL siRNA-transfected cells and obtained from four independent experiments (<italic>H</italic>). In all graphs, values represent the mean &#177; S.E., and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p>
###xml 9 1632 9 1609 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52"><bold>Effects of</bold> &#946;<bold>-arrestin-2 knocking down on AngII-induced interaction of BAD with its partners in AT<sub>1A</sub>R-stably expressing HEK-293 cells.</bold> Cells were transfected with either control (<italic>CTL</italic>) or &#946;-arrestin-2 (&#946;<italic>arr2</italic>) siRNA. After transfection, cells were serum-starved for &#8764;6 h and then stimulated with 100 n<sc>m</sc> AngII for 30 min. <italic>A</italic>, cell lysates were prepared and used for immunoprecipitation (<italic>IP</italic>) with a 14-3-3 antibody. The BAD protein co-immunoprecipitated with 14-3-3 was visualized by immunoblotting (<italic>IB</italic>) (<italic>upper blot</italic>), and its amount in each sample was quantified and normalized by the amounts of BAD in input lysates (<italic>lower blot</italic>). <italic>B</italic>, values were expressed as folds over the basal level obtained in non-stimulated (<italic>NS</italic>), CTL siRNA-transfected cells. Data were obtained from four independent experiments. <italic>C-F</italic>, after immunoprecipitation with a BAD antibody, co-immunoprecipitated 14-3-3 (<italic>C</italic>) and Bcl-xL (<italic>E</italic>) proteins with BAD were visualized, and their amounts were determined as described for <italic>A. D</italic>, data were expressed as folds over the basal level and obtained from three independent experiments. <italic>F</italic>, values were expressed as percent of the basal level and obtained from four independent experiments. <italic>G</italic> and <italic>H</italic>, phosphorylation of BAD at Ser<sup>75</sup> in each lysate used for immunoprecipitation experiments were visualized (<italic>G</italic>) and measured (<italic>H</italic>). Data were expressed as percent of the response to AngII in CTL siRNA-transfected cells and obtained from four independent experiments (<italic>H</italic>). In all graphs, values represent the mean &#177; S.E., and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p></caption>
###xml 1632 1632 1609 1609 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0170971160005"/>
###xml 0 1632 0 1609 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="52"><bold>Effects of</bold> &#946;<bold>-arrestin-2 knocking down on AngII-induced interaction of BAD with its partners in AT<sub>1A</sub>R-stably expressing HEK-293 cells.</bold> Cells were transfected with either control (<italic>CTL</italic>) or &#946;-arrestin-2 (&#946;<italic>arr2</italic>) siRNA. After transfection, cells were serum-starved for &#8764;6 h and then stimulated with 100 n<sc>m</sc> AngII for 30 min. <italic>A</italic>, cell lysates were prepared and used for immunoprecipitation (<italic>IP</italic>) with a 14-3-3 antibody. The BAD protein co-immunoprecipitated with 14-3-3 was visualized by immunoblotting (<italic>IB</italic>) (<italic>upper blot</italic>), and its amount in each sample was quantified and normalized by the amounts of BAD in input lysates (<italic>lower blot</italic>). <italic>B</italic>, values were expressed as folds over the basal level obtained in non-stimulated (<italic>NS</italic>), CTL siRNA-transfected cells. Data were obtained from four independent experiments. <italic>C-F</italic>, after immunoprecipitation with a BAD antibody, co-immunoprecipitated 14-3-3 (<italic>C</italic>) and Bcl-xL (<italic>E</italic>) proteins with BAD were visualized, and their amounts were determined as described for <italic>A. D</italic>, data were expressed as folds over the basal level and obtained from three independent experiments. <italic>F</italic>, values were expressed as percent of the basal level and obtained from four independent experiments. <italic>G</italic> and <italic>H</italic>, phosphorylation of BAD at Ser<sup>75</sup> in each lysate used for immunoprecipitation experiments were visualized (<italic>G</italic>) and measured (<italic>H</italic>). Data were expressed as percent of the response to AngII in CTL siRNA-transfected cells and obtained from four independent experiments (<italic>H</italic>). In all graphs, values represent the mean &#177; S.E., and statistical analyses were carried out as described under &#8220;Experimental Procedures.&#8221;</p></caption><graphic xlink:href="zbc0170971160005"/></fig>
FIGURE 5.Effects of beta-arrestin-2 knocking down on AngII-induced interaction of BAD with its partners in AT1AR-stably expressing HEK-293 cells. Cells were transfected with either control (CTL) or beta-arrestin-2 (betaarr2) siRNA. After transfection, cells were serum-starved for approximately6 h and then stimulated with 100 nm AngII for 30 min. A, cell lysates were prepared and used for immunoprecipitation (IP) with a 14-3-3 antibody. The BAD protein co-immunoprecipitated with 14-3-3 was visualized by immunoblotting (IB) (upper blot), and its amount in each sample was quantified and normalized by the amounts of BAD in input lysates (lower blot). B, values were expressed as folds over the basal level obtained in non-stimulated (NS), CTL siRNA-transfected cells. Data were obtained from four independent experiments. C-F, after immunoprecipitation with a BAD antibody, co-immunoprecipitated 14-3-3 (C) and Bcl-xL (E) proteins with BAD were visualized, and their amounts were determined as described for A. D, data were expressed as folds over the basal level and obtained from three independent experiments. F, values were expressed as percent of the basal level and obtained from four independent experiments. G and H, phosphorylation of BAD at Ser75 in each lysate used for immunoprecipitation experiments were visualized (G) and measured (H). Data were expressed as percent of the response to AngII in CTL siRNA-transfected cells and obtained from four independent experiments (H). In all graphs, values represent the mean +/- S.E., and statistical analyses were carried out as described under "Experimental Procedures."
###end p 51
###begin p 52
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of</bold>
###xml 100 102 97 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 15 136 12 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-arrestin-2 knocking down on AngII-induced interaction of BAD with its partners in AT<sub>1A</sub>R-stably expressing HEK-293 cells.</bold>
###xml 181 184 178 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTL</italic>
###xml 210 214 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arr2</italic>
###xml 319 320 298 299 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 339 340 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 403 405 382 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IP</italic>
###xml 515 517 494 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 520 530 499 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper blot</italic>
###xml 633 643 612 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower blot</italic>
###xml 646 647 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 729 731 708 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 817 820 796 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C-F</italic>
###xml 899 900 878 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 914 915 893 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1003 1007 982 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. D</italic>
###xml 1108 1109 1087 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1211 1212 1190 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1217 1218 1196 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1249 1251 1228 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">75</sup>
###xml 1325 1326 1304 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1342 1343 1321 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1481 1482 1460 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
Effects of beta-arrestin-2 knocking down on AngII-induced interaction of BAD with its partners in AT1AR-stably expressing HEK-293 cells. Cells were transfected with either control (CTL) or beta-arrestin-2 (betaarr2) siRNA. After transfection, cells were serum-starved for approximately6 h and then stimulated with 100 nm AngII for 30 min. A, cell lysates were prepared and used for immunoprecipitation (IP) with a 14-3-3 antibody. The BAD protein co-immunoprecipitated with 14-3-3 was visualized by immunoblotting (IB) (upper blot), and its amount in each sample was quantified and normalized by the amounts of BAD in input lysates (lower blot). B, values were expressed as folds over the basal level obtained in non-stimulated (NS), CTL siRNA-transfected cells. Data were obtained from four independent experiments. C-F, after immunoprecipitation with a BAD antibody, co-immunoprecipitated 14-3-3 (C) and Bcl-xL (E) proteins with BAD were visualized, and their amounts were determined as described for A. D, data were expressed as folds over the basal level and obtained from three independent experiments. F, values were expressed as percent of the basal level and obtained from four independent experiments. G and H, phosphorylation of BAD at Ser75 in each lysate used for immunoprecipitation experiments were visualized (G) and measured (H). Data were expressed as percent of the response to AngII in CTL siRNA-transfected cells and obtained from four independent experiments (H). In all graphs, values represent the mean +/- S.E., and statistical analyses were carried out as described under "Experimental Procedures."
###end p 52
###begin p 53
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 866 868 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref50">50</xref>
###xml 970 972 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 1157 1159 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 1374 1376 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 1521 1523 1482 1484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 721 726 <span type="species:ncbi:9606">human</span>
###xml 841 846 <span type="species:ncbi:9606">human</span>
###xml 1151 1155 <span type="species:ncbi:10090">mice</span>
###xml 1250 1254 <span type="species:ncbi:10090">mice</span>
###xml 1483 1487 <span type="species:ncbi:10090">mice</span>
Apoptosis of VSMCs plays a significant role in vascular remodeling as well as in vascular diseases, including atherosclerosis and neointima formation after injury, which are also associated with cell proliferation (34, 48, 49). AngII is a well known cell survival factor for VSMCs (28, 29, 34). Our data establish a mechanism by which AngII leads to cellular protection as well as demonstrate that beta-arrestin-2 is a key mediator of this mechanism. Our results thus suggest that beta-arrestin-2 may play an important role in vascular diseases and remodeling, and raise the possibility that beta-arrestins may represent a therapeutic target in such diseases. Several previous findings support this idea. Atherosclerotic human coronary arteries show up-regulated (approximately2-fold higher) beta-arrestin-2 mRNA levels compared with normal human coronary arteries (50). beta-Arrestin-2 appears to be the predominant beta-arrestin isoform in the atherosclerotic lesion (48). Moreover, deficiency of beta-arrestin-2 leads to reduced aortic atherosclerosis and a decrease in the prevalence of atheroma SMCs in low density lipoprotein receptor-deficient mice (48). In agreement with our results, it also has been reported that beta-arrestin-2 knock-out mice show augmented medial SMC apoptosis in carotid arteries after endothelial denudation to induce neointimal hyperplasia (48). Furthermore, ERK and AKT activation in SMCs of injured arteries is reduced in beta-arrestin-2 knock-out mice compared with wild-type animals (48).
###end p 53
###begin p 54
###xml 149 150 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
In summary, the present study reveals anti-apoptosis as a physiological consequence of beta-arrestin-mediated signaling upon activation of the 7TM AT1 receptor, and delineates the beta-arrestin-2-mediated anti-apoptotic pathways. These results also provide better understanding of the role of beta-arrestin-2 in apoptosis-related vascular diseases at the molecular level and may allow the development of therapeutic agents that target the beta-arrestins for such diseases.
###end p 54
###begin title 55
Supplementary Material
###end title 55
###begin title 56
[Supplemental Data]
###end title 56
###begin p 57
We thank Dr. Jeffrey J. Kovacs for critical reading of the manuscript and helpful comments. We also thank Donna Addison and Elizabeth Hall for excellent secretarial assistance.
###end p 57
###begin p 58
###xml 85 86 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 329 330 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 339 340 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 170 175 <span type="species:ncbi:9606">human</span>
The abbreviations used are: 7TMR, 7-transmembrane receptor; AngII, angiotensin II; AT1R, angiotensin II type 1 receptor; ERK, extracellular signal-regulated kinase; HEK, human embryonic kidney; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; RSK, ribosomal S6 kinase; SII, [Sar1,Ile4,Ile8]angiotensin II; siRNA, small interfering RNA; VSMC, vascular smooth muscle cell; Z, benzyloxycarbonyl; fmk, fluoromethyl ketone; PBS, phosphate-buffered saline.
###end p 58
###begin p 59
S. Ahn and R. J. Lefkowitz, unpublished data.
###end p 59

